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ABSTRACT 
 Substandard and counterfeit medicines are major obstacles to the treatment of 
infectious diseases. Substandard medicines vary from standard drugs in terms of dose, 
bioavailability, or the presence of impurities. Current methods to identify substandard 
and counterfeit antimicrobial drugs are either resource intensive or have poor specificity. 
This dissertation examined two issues related to poor quality antimicrobial medicines: 1) 
Methods to detect and prevent the consumption of substandard drugs. 2) The relationship 
between substandard medicines and the evolution of rifampicin resistance. This 
dissertation advanced two technologies that may aid in the detection of substandard 
medicines: aptamers and biosensors. Oligonucleotide aptamers may be adapted for drug 
detection by coupling binding events to changes in fluorescence, luminescence or 
colorimetric signals. A computational model was developed to discover experimental 
factors that increase the probability of selecting a high affinity aptamer. Among them are: 
micromolar drug target concentration, high affinity substrate to partition aptamers, and 
high aptamer library affinity distribution. Random losses of aptamers due to experimental 
	
	 vi 
noise greatly decreased the probability of selecting an aptamer. Experimental parameters 
to optimize the process of aptamer discovery for small molecules are discussed. Bacterial 
biosensors are an alternative strategy for the detection of active pharmaceutical 
ingredients. Here, luciferase-expressing Escherichia coli were used to create profiles of 
drug interactions for anti-mycobacterial drugs. Drug interactions were tested by the 
Loewe additivity model. A novel method to differentiate rifamycin drugs from the drug 
degradation product rifampicin quinone was developed by analyzing each drug’s unique 
interactions.  
While subinhibitory drug doses are known to select for antimicrobial resistance in 
vitro, the role of substandard anti-mycobacterial medicines in the development of 
rifampicin resistance remains poorly understood. The role of the drug degradation 
product rifampicin quinone on rifamycin resistance was assessed through in vitro studies 
of bacteria. Wild type Escherichia coli and Mycobacterium smegmatis cultured in the 
presence of rifampicin quinone acquired high levels of resistance to rifamycin drugs. 
Resistance was associated with genetic mutations in the rifampicin resistance cluster of 
the rpoB gene. The studies presented here demonstrate that substandard medicines can 
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CHAPTER 1: Introduction 
Prevalence of substandard and counterfeit anti-mycobacterial drugs 
	 Substandard and counterfeit medicines are major obstacles to the treatment of 
infectious diseases in the developing world. Counterfeit medicines are illicit copies of 
genuine medicines that are unlikely to contain active pharmaceutical ingredients (1). 
Besides lacking their stated active ingredients, counterfeit medicines may contain other 
drugs, or toxic impurities  (2). Substandard medicines vary from standard drugs in terms 
of dose, bioavailability, or the presence of synthetic byproducts, degradation products or 
impurities (3). Substandard medicines may arise due to poor formulations or due to post 
manufacturing issues such as drug expiry and improper storage conditions (4). Chemical 
instability of drugs may lead to substantial loss of active pharmaceutical ingredients, 
especially under poor storage conditions (5). 
Antimicrobial agents are among the most prevalent drugs to be counterfeit or 
substandard (4). Approximately 25% of medicines in low and middle- income countries 
are counterfeit or substandard, the majority of which are antimicrobial agents (6). Among 
antimicrobial agents, anti-tuberculosis drugs have a very high impact on global health 
given the annual incidence of tuberculosis is approximately ten million cases (7, 8). 
Counterfeit and substandard medicines are more prevalent in the regions of the world 
most plagued by infectious diseases (9).  
A recent meta-analysis of reports of substandard medicines found that 28 
countries had reports of substandard of counterfeit anti-tuberculosis drugs, the majority of 




samples that were analyzed in this region, 9% of registered products had inadequate dose 
or bioavailability, the failure rate went up to 29% for unregistered products as measured 
by disintegration  (11). The failure rate ranged from 4% in middle income countries to 
10% in India and 17% in Africa. Approximately half of the failed products were falsified 
medicines and the remainder contained subtherapeutic doses of drugs. 
The frequency of poor drug quality may vary depending on formulation as well as 
location. A study of the quality of anti-mycobacterial medicines in Tamil Nadu India 
showed that the rate of substandard rifampicin from 8% in 150 mg tablets to 20% in in 
450 mg tablets (12). A World Health Organization study of anti-mycobacterial drugs in 
former Soviet Union states found that rifampicin containing tablets had the greatest 
quality failure rate of 28% (13). In a Botswana convenience sample, 31% of fixed dose 
combination therapies containing rifampicin failed quality testing by thin layer 
chromatography  (14). A study of drugs from Nigerian pharmacies found that nearly half 
of tested antimicrobial drugs were not within British Pharmacopeia standards, and one 
third of the tested rifampicin capsules had the wrong dose of active ingredient (15). 
Substandard antimicrobials and clinical outcomes 
	 Poor quality antimicrobial drugs undermine the treatment of infectious disease, 
and may thereby lead to patient level and population level poor health outcomes  (6). 
Drug degradation products may partially or fully replace the standard active 
pharmaceutical ingredient, resulting in a diminished dose to patients  (16). One study 
identified a case of ‘false’ chloroquine resistance, wherein drug sensitive plasmodia 




Depending on their therapeutic range, substandard drugs may or may not impact 
individual treatment. Illnesses such as malnutrition can exacerbate the problem of low 
dose medicines, due to its role in reduction of drug bioavailability  (18). Rifampicin is 
considered to have a narrow therapeutic index due to the relatively small range between 
therapeutic doses and toxicity inducing doses  (19). Rifampicin is a strong inducer of 
cytochrome p450, and an inhibitor of oat drug transporter and thereby mediates many 
adverse drug interactions  (20). Rifampicin is therefore an especially risky drug, whether 
present in poor quality medicines in abnormally high or low doses.  
In addition to potential treatment failures and toxicity on the individual treatment 
level, substandard medicines may also contribute to antibiotic resistance worldwide. 
Under-dosing is a known contributor to the selection of antibiotic resistant microbes in 
vitro (21). Countries with a high level of drug resistant microbes coincide with regions 
with poor quality antimicrobial drugs  (22, 23). A meta-analysis of four cohort studies 
had insufficient data to assess the impact of drug quality on the development of MDR-TB  
(24). Therefore, additional studies are required to determine the influence the impact of 
substandard rifampicin on the development of antibiotic resistant mycobacteria. 
Use of rifampicin as a broad-spectrum antibiotic 
	 Rifampicin is a semisynthetic drug in the rifamycin class. Rifampicin works by 
binding the DNA dependent RNA polymerase, and thereby prevents elongation of 
mRNA transcripts  (25). Given the extent to which the DNA dependent RNA polymerase 
is conserved within bacteria, rifampicin is a broad spectrum antibiotic. Hundreds of 




tuberculosis  (26). Rifampicin may be used as a prophylaxis against staphylococcal and 
meningococcal infections, and has efficacy against E. coli and pseudomonas  (27, 28). 
The use of rifampicin as an effective antibacterial agent is threatened by the 
development of drug resistant microbes. There are many factors that are associated with 
drug resistance in mycobacteria, ranging from host determinants such as immune status 
and adherence, and population factors such as HIV rate, host-pathogen sympatry and 
local efforts to control disease  (29). Substandard medicines contribute to these factors by 
hindering efforts to control disease, and undermining patient trust in the medical system 
that may materialize in poor adherence and decreased tendency to seek professional care  
(30).  
Another large factor in the development of drug resistance in mycobacteria is the 
influence of treatment on the bacteria. Clinical treatment of active tuberculosis is 
associated with a biphasic decrease in bacteria number; the initial decrease due to the 
reduction in drug sensitive bacteria, leaving a residual population of persister cells  (31). 
Drug treatments can result in changes to bacterial transcription, metabolism, and cell wall 
components and may select for resistance conferring mutations  (29).  
Spontaneous mutations occur in Mycobacterium tuberculosis at the rate of 10-10 
for dormant populations and up to 1 order of magnitude more frequently in actively 
dividing populations  (32). The vast majority of rifampicin resistance in Mycobacterium 
tuberculosis is associated with mutations in the rpoB gene, which encodes the Beta 
subunit of the DNA dependent RNA polymerase  (33). Rifampicin has a close 




assessed by X-ray crystallography  (25). Mutations in the rpoB gene disrupt this binding 
site, thereby decreasing the affinity of rifampicin to its target. An 81 base pair span of the 
gene is particularly enriched for resistance conferring mutations and is thereby deemed a 
‘resistance cluster’. Two other resistance clusters also reside in the rpoB gene. Amino 
acids 516, 526 and 531 of the rpoB gene (using E. coli gene mapping notation) have a 
particularly high co-occurrence with rifampicin resistance in Mycobacteria  (33). 
Depending on the specific rpoB mutant alleles, rifampicin resistant Mycobacteria 
have variable levels of resistance to rifabutin and rifapentine, which are other rifamycin-
derived drugs  (34). The phenomenon of cross-resistance occurs when bacteria gain 
resistance to an antibiotic it has not been exposed to after gaining resistance to another 
antibiotic  (34). Cross-resistance is common among antibiotics from similar classes (35). 
Competition experiments with radiolabeled drugs in E. coli demonstrate that rifampicin, 
rifabutin and rifapentine all share a common binding site on RNA polymerase (36). 
Rifampicin degradation to rifampicin quinone 
	 Rifampicin’s main degradation product occurs from non-enzymatic auto-
oxidation to form rifampicin quinone  (37). Besides rifampicin quinone, degradation of 
rifampicin may also produce rifampin n-oxide, 5-desacetyl rifampicin, and rifampin SV. 
Rifampicin quinone was the most common degradation product found by HPLC analysis 
of substandard medicines found in the former Soviet Union territories of Armenia, 
Azerbaijan, Belarus, Kazakhstan, Ukraine, and Uzbekistan  (13). 
Rifampicin is the least stable component of fixed dose combinations that also 




heat, humidity and buffer choice all influence the rate of degradation. Rifampicin 
undergoes rapid auto-oxidation in the presence of Tris buffers, which is a limit to some 
experimental studies using rifampicin  (39). In forced degradation studies with .1M 
hydrochloric acid treatment, 25-33% of rifampicin content was lost from mono and 
combination tablets, as measured by HPLC. Another study of forced degradation under 
1M hydrochloric acid or 1M sodium hydroxide found rifampicin primarily converted to 
rifampicin quinone and rifampin SV  (40). In non-oxidative environments, rifamycin SV 
is more likely to form, while in oxidative environment, rifampicin quinone is the more 
prevalent degradation product  (41). 
The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use describes accelerated degradation conditions as 
temperatures of 40 degrees Celsius and 75% humidity or greater. This environment has 
indeed been shown to accelerate the degradation of anti-mycobacterials such as 
rifampicin and isoniazid  (42). A study of medicine quality in India found that light 
exacerbates drug degradation, based on rifampicin content evaluated by HPLC. In 
ambient temperatures, there was less than 10% loss of active ingredient over 3 months. 
However, with heat, humidity and light exposure over the same period of time, up to 85% 
of the rifampicin degraded  (43). Proper packaging can attenuate the degradation 
conditions; another study found only 15% loss of rifampicin over several months for 6 
different drug formulations  (44). The presence of isoniazid in fixed dose combinations is 




Many rifampicin-related compounds have some antimicrobial activity, though 
their affinity to RNA polymerase may vary widely  (25). Rifampicin quinone is bioactive 
and inhibits RNA polymerase, with a KD of approximately 1 uM  (39). Rifampicin 
quinone may have deleterious in vivo effects, as it has shown immunosuppression in 
animal models (46). Rifampicin quinone is also thought to underlie some of the toxicity 
and adverse drug interactions commonly associated with rifampicin  (47, 48). 
Biochemical methodologies for active pharmaceutical ingredient detection 
	 High performance liquid chromatography (HPLC) is a gold standard method to 
verify the concentration of active ingredients of pharmaceuticals. HPLC is a resource 
intensive process requiring customization of solvents, columns and elution time for 
varying tablet formulations. Acetonitrile and methanol are common toxic reagents that 
are used in the process of HPLC, which may be of poor accessibility and leave an 
environmental impact in low and middle-income countries. An adaptation of US 
Pharmacopeia HPLC guidelines allowed for resolution of rifampicin from its degradation 
products with a half hour run time for each tablet  (38). An expedited version of the 
methodology cut the elution time to 11 minutes in order to differentiate rifampicin from 
rifampicin quinone and rifampin SV  (40). NMR is another methodology that provides 
quantitative data regarding drug tablet content. NMR can distinguish between varying 
rifamycin drugs as well as formulation variations that may underlie differences in drug 





Thin layer chromatography is a semi-quantitative method used to assess drug 
quality. The global pharma health fund MiniLab is currently in supply to about 90 
countries as a measure to detect counterfeit and substandard drugs by thin layer 
chromatography. They advise screening based on tablet appearance, disintegration and 
performance on thin layer chromatography  (51). This methodology can only detect 
absolute fake drugs and grossly substandard medicines that have less than 80% the stated 
active ingredient  (52). A study of antimalarials in Gabon found that 2 artemesinin-based 
drugs that failed the MiniLab test had no active ingredient as confirmed by HPLC testing  
(53). Thin layer chromatography identified many low dose rifampicin-containing drugs in 
a convenience sample on combination tuberculosis medicines, but was unable to identify 
tablets with high doses of drugs  (14). High performance thin layer chromatography is 
capable of resolving rifampicin from rifampicin quinone, in a methodology that is less 
time and resource intensive than HPLC , but less sensitive (45, 54). However, these 
assays are not broadly accessible in the developing world. 
Colorimetric assays are a simple, if not highly specific means to identify 
counterfeit drugs  (55). As they do not provide quantitative data, colorimetric assays are 
not sensitive enough to distinguish substandard medicines from standard. The recently 
developed paper analytic device had 85% sensitivity. This device identifies rifampicin 
through a reaction with iron(III), and may be of use in low resource settings to identify 




Nucleic acid aptamers for active pharmaceutical ingredient detection 
	 Experimental devices utilize signaling molecules to identify substandard and 
counterfeit drugs. These devices require specific signaling molecules to probe for the 
presence of drug products. As most antimicrobial agents are small molecules, novel 
approaches to detection are required, as antibodies cannot typically be utilized for such 
compounds. Given the immense experimental challenges in the discovery of novel probes 
for small molecules, we generated a computational model to optimize experimental 
parameters for this process. 
	 Nucleic acids are a potential alternative to antibodies for sensitive and specific 
detection of small molecule drugs. Nucleic acids that bind specifically to other molecules 
have been coined aptamers  (57). The first aptamers to be discovered were composed of 
RNA. RNA aptamers are desirable for their great range of conformation and potential 
catalytic activity  (58), while DNA aptamers have preferable stability  (59, 60).  
Aptamers for small molecules may be adapted for the detection of drugs via the 
conjugation of fluorescence markers or the modification of chemiluminescence assays, 
while some aptamers enhance fluorescence of other molecules  (61). One such example is 
the detection of the environmental toxin acetamaprid at concentrations as low as 62 pM 
with peroxide and luminol on gold nanoparticles with bound aptamers providing a 
chemiluminescence signal  (62). An aptamer for tetracycline was adapted for a 
colorimetric assay to detect tetracycline  (63, 64).  
Aptamers are selected through the iterative screening of random libraries 




EXponential Enrichment describes the methodology used to select aptamers with high 
affinity to ligands from an initial library of nucleic acid sequences of unknown affinity to 
the ligand  (65). Ligands are incubated with the target, and those that exhibit preferential 
binding are amplified for the next round of selection. Through 10-20 rounds of selection, 
an initial library can be reduced to a handful of high-affinity aptamers  (66). Aptamers 
typically contain conserved sequences for amplification, and random regions for binding 
to the ligand of interest. While many aptamer selection methods utilize immobilized 
ligand, this is not feasible for small molecule targets. Aptamer candidates may be 
immobilized on a substrate material such as graphene oxide or via docking sequences on 
streptavidin beads to facilitate separation of target-bound and unbound ligands  (67).  
Many variables of the aptamer selection process influence the likelihood of 
successfully identifying an aptamer with affinity to a ligand of interest. The length of 
docking sequences, primer binding sites and length and number of random regions in the 
aptamer library may all affect selection outcome  (68). After selection, the truncation of 
aptamers can affect affinity to the ligand  (69). Experimental parameters such as ligand 
concentration, binding substrate of choice, wash stringency and amplification protocols 
can all impact whether an aptamer survives to the next round of selection or becomes 
mutated or lost in process  (70-72). 
Bacterial biosensors for active pharmaceutical ingredient detection 
Biosensors use living systems to transduce an environmental signal into a change 
in phenotype. Cells may be modified by incorporation of colorimetric, luminescence or 




of a molecule with a measurable response  (73). Bacteria based biosensors are inherently 
reproducible and are low cost to maintain and propagate.  
Biosensors have been developed for the detection of environmental toxins using 
E. coli. E. coli carrying a tetracycline inducible plasmid with 3 different reports can 
provide different signals (colorimetric, fluorescent or luminescence) depending on the 
concentration of tetracycline in milk  (74). A suite of E. coli biosensors with a 
luminescence reporter can detect heavy metal contaminants such as mercury, zinc, 
cadmium and lead, copper  (75). Some of the reporters were promiscuous for multiple 
heavy metals while others were specific to a single toxin. Other organisms such as 
Proteus mirabilis and Bacilus subtilis are also adaptable for small molecule detection 
systems  (76, 77). 
Using reporters for specific drug mechanisms of action, bacteria may be adapted 
to detect antimicrobial drugs. RecA coupled to green fluorescent protein (GFP) has been 
used for the detection of inhibitors of DNA metabolism in bacteria  (78). The strength of 
fluorescence output was useful to differentiate gyrase inhibitors from ligase inhibitors. A 
pharmaceutical company was able to classify drugs based on their stimulation of several 
luminescence-coupled promoters in B. subtilis  (77). DNA damaging agents were 
identified by luminescence of the yorB promoter, RNA targeting agents identified by the 
yvgS promoter, protein synthesis inhibitors associated with luminescence of the yheI 
promoter. Cell wall inhibitors and fatty acids synthesis inhibitors were associated with 




studying drugs targeting RNA polymerase further validated this methodology, comparing 
drugs with known and unknown mechanism of action  (79). 
Drug interaction testing for antimicrobial detection 
	 Recent studies suggest that drug interaction profiles (the drug interaction scores 
for a particular drug against a panel of other drugs) are unique even for drugs with the 
same mechanism of action and may therefore be harnessed to identify antimicrobial 
compounds  (80, 81). Drug interactions are defined by a combined effect that is different 
than expected. A drug interaction score may be computed based on the comparison of the 
expected vs. the observed phenotype for the drug combination [log2(observed/expected)]. 
For the growth inhibition phenotype, the interaction score is 0 when the observed growth 
equals expected, negative when observed growth is less than expected and positive when 
observed growth is greater than expected.  
The expected phenotype of drug combinations varies based on model. According 
to the Bliss independence model, the relative effect of a drug is independent of the other 
drug’s activity  (82). For the growth phenotype, if two drugs each inhibit cellular growth 
by 50% each (IC50), their expected combined effect is 75% growth inhibition (1 - 
0.5*0.5). Experimentally, drug interactions may be tested using the Bliss independence 
model in a simple 2x2 setup of drug 1, drug 2, drug 1 + drug 2, and a drug free control. 
According to the Loewe additivity model of drug interactions, a drug is not 
expected to interact with itself  (83). Drug interactions are classically tested in an 8x8 
checkerboard assay of dose combinations, with each of the 2 drugs increasing on each 




contours for growth are expected to have 0 concavity for any given inhibitory 
concentration level and high correlation of growth across the symmetry axis. 
Isophenotypic contour concavity with deviation from 0 therefore indicates that an 
unknown drug is not equivalent to the known drug. Under the Loewe additivity model, 
drug interactions may also be determined using a sampling of the checkerboard, by 
comparing the dose response of the drug combination to the individual dose responses of 
the individual drug components. The Loewe additivity model is more stringent for 
identifying negative interactions. For example, the expected growth inhibition for the 
combination of 2 drugs at IC50 is complete inhibition, in comparison with the 75% 







Figure 1.1: Classification of drug interactions. 
Displayed are representative interaction experiments with growth curves superimposed 
on a heat map for normalized growth level (0 at minimal inhibitory concentration, 1 at 
drug-free condition). According to the Loewe additivity model of drug interactions, the 
concavity of isophenotypic curves for growth level is expected to be significantly less 
than or greater than linear for synergistic and antagonistic drug interactions, respectively. 
‘Self-self’ experiments, in which the same drug is increased on each axis, define the 
experimental assay variability and define the 95% confidence interval for additive drug 
interactions. At the left is the self-self experiment of drug 1+drug 1 combined with itself; 
note the straight isophenotypic curve. At middle is drug 1+drug 2, the negative 
isophenotypic curve indicating a synergistic relationship. At right, drug 1+drug 3, the 






Yeh et al. conducted one of the largest systematic screens of drug combinations in 
E. coli and assessed all pairwise interactions of 21 antibacterial drugs using the Bliss 
independence model  (80). Inspection of the data indicates that drug interaction profiles 
(drug interaction scores for a particular drug against a panel of other drugs) are unique. 
For example, doxycycline and tetracycline are both 30S ribosome protein synthesis 
inhibitors in E. coli, yet they have varying interaction scores with ampicillin and the 
majority of the other twenty drugs. Large arrays of drug interactions may therefore create 
a fingerprint for the purpose of identifying active pharmaceutical ingredients. 
Dissertation Research Specific Aims 
Due to the significant impact of substandard drugs on global health, and the 
limitations of current technologies for use in low-resource settings, there is interest in 
developing new technologies that could be particularly useful in field settings in resource 
poor countries.  This led to investigations into the selection process for aptamers for 
small molecule drugs (Chapter 2). Thematically linked to this issue, was interest in 
creating accurate yet simpler methods for identifying drugs and drug degradation 
products using a bioassay (Chapter 3). Lastly, data are presented regarding the 
consequences of substandard drugs using an in vitro model that maps the acquisition of 
resistance to rifampicin due to exposure to its primary oxidative degradation product, 
rifampicin quinone (Chapter 4). These data validate concerns that substandard drugs 
could lead to higher rates of drug resistance to the primary compound, and contribute to 




 Specific Aim 1: To assess selection strategies for DNA aptamers for small 
molecule drug detection. 
Hypothesis: Experimental parameters including target concentration, library 
affinity distributions and random events can influence the successful enrichment of DNA 
aptamers to small molecule targets. 
Approach: The capture-SELEX method served as the basis of our computational 
model of selection dynamics. An aptamer library containing ~1015 unique sequences was 
incubated with a substrate and allowed to equilibrate with a small molecule target ligand. 
There was therefore competition between the substrate and small molecule for binding to 
aptamer candidates. Aptamers that were unbound due to ligand binding or random events 
from the substrate were partitioned, amplified and prepared for additional rounds of 
selection. The affinity of the aptamers to the small molecule target was expected to 
increase with each selection cycle. Our model analyzed the influence of the initial 
aptamer affinity distribution and target concentration on the probability of selecting high 
affinity aptamer through the capture-SELEX method. 
Specific Aim 2: To determine whether anti-mycobacterial drugs may be identified 
based on drug interaction profiles in E. coli. 
Hypothesis: Drug interactions between rifamycin compounds and other drugs can 
be used to create a unique drug interaction fingerprint for drug quality assurance.  
Approach: Wild-type E. coli with a luciferase expressing plasmid were cultured in 
vitro with combinations of 13 antibiotics with 4 rifamycin drugs or the drug degradation 




tested by comparing shifts in dose response for drug combinations versus single drug 
effects. Dose response were assessed for each single drug and combination (a one to one 
mixture) with linear dilutions. Drug combinations were an equal mixture of single agents 
containing approximately one half minimal inhibitory concentration of each single agent. 
Dose-response curves were generated based on the area under the luminescence curve, 
standardized to the drug free condition, over a one-hour interval. All doses were adjusted 
to fraction of minimal inhibitory concentration from zero to one. The drug interaction 
score was approximated by the fractional inhibitory concentration index, using the Loewe 
additivity model, which assumes that a drug cannot interact with itself. Drug interaction 
profiles were composed of arrays of drug interaction scores for each rifamycin drug or 
degradation product tested with other antibiotic compounds. All experiments were done 
in replicate. Drug identification was based on similarity of a query drug interaction 
profile to the known drug interaction profiles. 
Specific Aim 3: To determine whether exposure to rifampicin degradation 
products induces resistance to the standard antimicrobial rifampicin E. coli and M. 
smegmatis. 
Hypothesis: Exposure to rifampicin quinone will select for the evolution of 
antimicrobial resistance to rifampicin in E. coli and M. smegmatis. 
Approach:  Wild-type E. coli and M. smegmatis were cultured in vitro with the 
drug degradation product rifampicin quinone or subtherapeutic doses of rifampicin until a 
thirty fold change in minimal inhibitory concentration (MIC) was observed. Cells were 




MIC of treated cells to controls: log2(MICresistant/MICparental). Representative colonies from 
each population were isolated, sequenced and assessed for single nucleotide 
polymorphisms, insertion and deletions in the rifampicin resistance clusters of the rpoB 
gene, which allowed us to propose mechanistic causes of antimicrobial resistance and 
identify features of resistance induced by standard medicines versus degraded drugs. 
Cross-resistance to additional rifamycin antibiotics was assessed to evaluate cross-
resistance patterns of standard drugs versus impurities.  
The studies presented aimed to test the broader notion that substandard medicines 
contribute towards antimicrobial resistance, and proposed methodologies to identify 
substandard medicines.  
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Abstract 
 Oligonucleotide aptamers have increasing applications as a class of molecules that 
bind with high affinity and specificity to a target. Aptamers are typically selected from a 
large pool of random candidate nucleic acid libraries through competition for the target. 
Using a stochastic hybrid model, we are able to study the combined impact of important 
evolutionary success factors such as competition, randomness, and changes in the 
environment. Whereas the environment may be tuned with experimental parameters such 
as target concentration, competition varies with differences in the initial distribution of 
aptamer–target binding affinities, and random events can eliminate even the ligands with 
the highest affinity. The search for high-affinity aptamers for targets such as proteins, 
small molecules, or cancer cells remains a formidable endeavor. Systematic Evolution of 
Ligands by EXponential Enrichment (SELEX) offers an iterative process to discover 
these aptamers through evolutionary selection of high-affinity candidates from a highly 
diverse random pool. This randomness dictates an unknown population distribution of 
fitness parameters, encoded by the binding affinities, toward SELEX targets. Adding to 
this uncertainty, repeating SELEX under identical conditions may lead to variable 




high-affinity ligands. Here, we present a stochastic hybrid model that describes the 
evolutionary selection of aptamers to explore the impact of these unknowns. To our 
surprise, we find that even single copies of high-affinity ligands in a pool of billions can 
strongly influence population dynamics, yet their survival is highly dependent on chance. 
We perform Monte Carlo simulations to explore the impact of environmental parameters, 
such as the target concentration, on selection efficiency in SELEX and identify strategies 
to control these uncertainties to ultimately improve the outcome and speed of this time- 
and resource-intensive process. 
Introduction 
Understanding and exploiting target–ligand binding are bedrocks of the 
biomedical sciences and support a host of applications ranging from diagnostics, 
therapeutics, and drug discovery to biosensing, imaging, and gene regulation. Antibodies 
and rational design provide a constructive playground to develop these applications, yet 
there generally remains a paucity of strong and specific binders for the innumerable viral, 
protein, and small-molecule targets under investigation. 
Aptamers offer an alternative to antibodies, yet despite their growth (1–4), the 
discovery of high-affinity aptamers remains a challenge, especially for small-molecule 
targets (5, 6). Systematic Evolution of Ligands by EXponential Enrichment (SELEX) (7, 
8) is the premier framework for aptamer development and isolates high-affinity ligands 
from an initial library similar to how advantageous traits are enriched in a biological 
population through Darwinian selection. In a cyclic process, ligands are incubated with 




round. Target molecules are typically immobilized on a substrate material to facilitate 
easy separation of target-bound and unbound ligands. Through numerous rounds of 
selection, an initial library can be reduced to a handful of high-affinity aptamers. Nucleic 
acids comprise the vast majority of libraries used in SELEX, where sequence regions are 
randomized to generate tremendous structural diversity. Whereas this diversity underpins 
the evolutionary nature of SELEX, numerous works suggest that initial library design is a 
significant contributor to its overall success (9). 
Although conceptually simple, the practical application of SELEX is plagued by 
uncertainty. Despite the impact of library design, the initial affinity distribution for any 
library toward a specific target remains a priori unknown. Target immobilization further 
complicates the procedure, particularly for small molecules. In comparison with large 
molecular weight targets such as proteins (10), viruses (11), and whole cells (12, 13), the 
immobilization of small molecules eliminates ligand binding sites and is thus impractical. 
Newer approaches instead bind the library itself to a substrate material using noncovalent 
equilibrium binding, but this introduces the opportunity for competitive losses of high-
affinity ligands that are initially present in extremely low numbers. Wash steps and other 
experimental procedures may lead to further random losses, whereas nonspecific 
selection of ligands can counter environmental pressures and stall selection. In short, 
these uncertainties may quickly compound to apply tremendous risk toward the guarantee 
of successful selection. 
Mathematical modeling therefore has great potential to help understand the 




parameters and improve selection outcomes. Previous models have explored SELEX for 
protein targets, considering parameters such as target concentration (14–16), separation 
efficiency of target-bound and unbound ligand (17), nonspecific binding of DNA to 
target (18), and negative selection steps (19). These studies predict that, despite its 
experimental complexity, the evolutionary nature of SELEX guarantees selection of the 
highest affinity ligand from the initial library. However, these works focus primarily on 
the use of deterministic equilibrium equations (14), whereas the presence of ligands in 
low copy numbers and the role of other experimental uncertainties suggest the use of 
more fundamental stochastic models rather than deterministic approximations. 
Mathematically, the chemical master equation provides a framework to test this 
hypothesis and generalize the above-mentioned deterministic models to include intrinsic 
stochasticity (20). Whereas this approach could be applied toward a purely stochastic 
model for SELEX, the result cannot currently be solved analytically or simulated by 
conventional techniques such as the Gillespie algorithm (21), due to the large number of 
molecules present. These limitations are common for many stochastic multiscale 
problems in biology, chemistry, and physics; the development of novel analytic 
approximations or numerical techniques to address this problem is an important ongoing 
research topic (22). 
Using these ideas as our foundation, we introduce a hybrid model for aptamer 
selection that builds on the chemical master equation to introduce stochastic uncertainty 
in SELEX modeling. Here, ligands are separated into two categories of high and low 




equilibrium system, whereas in the latter it can be approximately solved analytically. 
Unlike previous efforts to incorporate stochasticity into aptamer modeling (23, 24), our 
framework allows us to simultaneously investigate the impact of low copy number 
ligands and their competitive binding to target molecules and immobilization substrates 
among the presence of high copy number ligands. Most importantly, this approach can 
capture total loss of individual ligands, which can strongly contribute to protocol 
outcome. Such events have not previously been investigated and cannot be captured by 
other approximations of the master equation such as the Langevin approximation, which 
rely on the presence of sufficiently high numbers of molecules and thereby diminish the 
possibility of extinction events (25). 
Using this framework, we investigate unexplored sources of uncertainty in 
SELEX, beginning with a systematic analysis of the role the initial library affinity 
distribution plays in selection. We further challenge the assumption that this distribution 
is continuous at its tails and evaluate the impact of adding noise at these extremes. We 
find that introducing as few as 20 additional ligands outside the bulk distribution of 1015 
molecules can strongly affect the outcome of selection. In light of these results, we revisit 
the topic of optimizing target concentration as discussed in previous works (14–16), and 
show that the assumed initial KD distribution strongly influences protocol optimizations. 
We also provide additional insights regarding noncovalent ligand immobilization to 
support more recent efforts to develop robust protocols for small-molecule SELEX (26–




concentration and the substrate binding dissociation constant over the SELEX cycles can 
lead to improved selection outcomes for a wide range of initial conditions.  
Materials and Methods 
Computational model of selection dynamics 
 The original SELEX protocol (7, 8) serves as the basis for our model, with 
additional modifications to accommodate small-molecule targets as described in ref. 26. 
Whereas this marks a model that specifically considers small-molecule targets, the main 
ideas and conclusions derived from this work remain applicable to other targets and 
selection schemes. The main steps of our approach are summarized in Fig. 2.1. We begin 
with a library of A∼toti ligands of type i, where i={1,…,MA} and MA is the total number of 
unique ligands. The ligands are then noncovalently immobilized using S∼tot substrate 
molecules, where KS is the ligand–substrate dissociation constant. These complexes are 
then subjected to wash steps to remove unbound ligands, from which A∼Ii ligands of type 
i survive. Surviving ligands are then incubated with T∼tot target molecules, where a ligand 
of type i binds to the target with a dissociation constant KD,i. Ligands that are bound to a 
target or have unbound from the substrate are partitioned from those that remain bound to 
the substrate. Finally, the partitioned ligands are amplified via PCR, modeled as a 
constant factor increase of αPCR, and used to begin the next cycle. The proceeding 
sections highlight the notable details of our hybrid approach, whereas a more thorough 




(SI). Throughout these sections, quantities that refer to an absolute number of molecules 







Figure 2.1: Capture SELEX Schematic 
Sample candidate library of ligands Ai is prepared by letting the ligands bind to a 
substrate S. Then, the target is added, leading to competitive binding between the 
different aptamers for substrate and target molecules T. The ligands still bound to the 
substrate are then separated from those that are either bound to a target, or have randomly 
unbound from the substrate. The latter two are subsequently amplified and taken into the 




Deterministic model of ligand binding  
 Earlier works use equilibrium conditions to characterize ligand–target interactions 
during selection (14–17), focusing on changes in bulk properties, such as the mean 
dissociation constant, to study the enrichment of a single best candidate. We instead 
monitor the full ligand affinity distribution in an effort to better understand how 
parameters such as the initial SD also impact selection dynamics. Because modeling each 
of the MA≈1015 unique ligands is computationally intractable, we discretize the initial 
distribution of MA unique ligands into MB bins, each containing A∼i ligands of 
dissociation constant KD,i, where i={1,…,MB}. We choose MB to be large enough that the 
results do not depend on the binning, and small enough to optimize simulation 
performance. We further build on this analysis by introducing additional equilibrium 
conditions for nonspecific ligand–substrate interactions represented by a dissociation 
constant KS. In ref. 26, substrate–ligand binding is accomplished through DNA base 
pairing using a fixed sequence, and is thus constant. Altering the length of this fixed 
sequence is a means to tune KS. Moreover, different immobilization techniques, such as 
the use of graphene oxide (27, 28), will lead to variations of KS within a given pool, but 
we do not consider such cases here and instead treat KS to be constant throughout a single 
cycle of SELEX. Combining ligand–target and ligand–substrate binding, the full system 
of steady-state equilibrium binding conditions can be described by the set of equations: 
[SAi]=1/KS(AIi−[SAi]−[TAi])Sfree, i=1,…,MB, 
[TAi]=1KD,i ((AIi−[SAi]−[TAi])Tfree, i=1,…,MB, 




 Here, [SAi] and [TAi] denote the concentration of ligand–substrate and ligand–
target complexes, representing 2MBindependent variables that are solved for; the 
quantities Ttot,Tfree and Stot,Sfree denote the concentrations of total and free target and 
substrate, respectively. From these results, we determine the concentration of ligands 
which survive selection, denoted by AS,Di, and are amplified by PCR for the next cycle. 
The superscripts denote that this number is obtained after selection and using the 
deterministic model defined by Eq. 1. This concentration is simply the sum of free- and 
target-bound ligands, and is hence given by 
AS,Di=[TAi]+Afreei= AIi−[SAi]. [2] 
Stochastic model of ligand selection  
Chemical reactions are fundamentally stochastic in nature, with forward and 
backward reactions occurring constantly. Whereas powerful and simple, Eq. 1 is based on 
real-valued concentrations which require sufficiently high molecular copy numbers to 
make discreteness and random fluctuations negligible. This is challenged at the tails of 
the KD distribution, where appropriate binning results in few ligands per bin. To address 
this, a hybrid approach is used where additional stochastic analysis is applied when Eq. 1 
predicts A∼S,Di to be below a threshold Θ. To distinguish these quantities for stochastic 
analysis, we denote them as A∼S,Dψ, where ψ represents the subset of indices i that 
satisfy the condition A∼S,Di<Θ. Results exploring the choice for Θ are provided in SI, 
Fig. 2.S6. We then calculate the probability for selecting A∼S,Sψ ligands, p(A∼S,Sψ); 




stochastic model. As described in the SI Appendix, we find that by starting with the 
chemical master equation, p(A∼S,Sψ) is well-approximated by a binomial distribution: 
p(A∼S,Sψ)=⎛⎝⎜⎜A∼totψA∼S,Sψ⎞⎠⎟⎟pA∼S,Sψψ(1−pψ)A∼totψ−A∼S,Sψ,forA∼S,Sψ=
0,…,A∼totψ. [3] 
Here, the quantity pψ represents the probability that a single ligand is selected out 
of A∼totψ ligands of type ψ. To provide the most accurate description, we account for 
stochastic contributions from both the immobilization and incubation steps. The 
contribution from immobilization is approximately the same for all candidates, and is 
given by A∼I/A∼tot, the fraction of remaining immobilized ligands after wash steps over 
those present before immobilization, where A∼I=∑MBi=1A∼Ii and 
A∼tot=∑MBi=1A∼totiA. The contribution from incubation is calculated as the fraction 
of predicted ligands, A∼S,Dψ, out of an initial number of A∼Iψ. Using these 
contributions, the total probability that a ligand in bin ψ survives is given by 
pψ=A∼IAS,DψA∼totAIψ. [4] 
Finally, Eq. 3 requires A∼totψ to be integer-valued, as it denotes a number of 
molecules. However, the deterministic equations yield real-valued concentrations that 
must be renormalized to an integer. We separate A∼totψ into its integer and fractional 
parts, A∼totψ=A∼totψ,ℕ+A∼totψ,fA, and then interpret 0≤A∼totψ,f<10≤A∼ψ,ftot<1 as 
the probability to have an extra molecule present. We then draw a uniformly distributed 




and A∼totψ=A∼totψ,ℕA otherwise. Following this renormalization, we finally draw a 
random variate distributed according to Eq. 3 to simulate the set of ligands A∼S,Sψ that 
remain after both immobilization and selection.  
Results 
Using a hybrid computational approach, our model provides a generalized 
framework that can be used to analyze both deterministic and stochastic effects in 
SELEX. We use the model to deconstruct two main forms of uncertainties in aptamer 
selection. The first is parameter uncertainty, including the unknown initial KD distribution 
as well as the experimentally tunable quantities Ks and Ttot. These are analyzed using a 
parameter study that observes the impact of these factors on SELEX dynamics. The 
second is stochastic uncertainty associated with low copy number binding phenomena. 
As this form of uncertainty is random in nature, we use Monte Carlo simulations to 
observe the variability in outcomes between repeated SELEX procedures and extract 
conclusions, which are robust with respect to stochastic fluctuations. Unless mentioned 
otherwise, the parameters from Table 2.S1 are used in all simulations. 
Effect of KD distribution on selection efficiency 
Gaussian distributions describing the initial ligand pool dominate SELEX models 
in literature (16), yet we are not aware of any prior systematic approach to study the 
impact of various distributions on the outcome of SELEX. Whereas strong justifications 
have been made for the assumption of a log-normal Gaussian description (29), we 




selection. Our convention for log-normal KD distributions is such that a Gaussian N(µ,σ) 
with mean µ and SD σ in log-space translates to a mean of 10µ in KD space; we do not 
shift the mean by (1/2)σ2 as is customary in Ito calculus. Fig. 2.2 highlights the dramatic 
difference observed for just two different assumed distributions, and demonstrates the 
significant role the initial KD distribution plays in SELEX. This point is further 
accentuated by the fact that different selection targets may significantly alter the initial 
KD distribution for any given library. SI, Fig. 2.S1 confirms that for a variety of other 
distributions, including non-Gaussians, distribution shape has a dramatic impact on 




Figure 2.2: Initial distribution affects SELEX dynamics. 
We plot the distribution of ligand binding affinities with increasing SELEX cycles for the 
same experimental parameters and two different assumed Gaussian distributions at cycle 
1, N(−3,0.4) (blue triangles) and N(−5,0.8) (red dots). The dynamics of the two cases are 
totally different. For N(−5,0.8), the distribution shifts to the left and becomes 
considerably narrower, while for N(−3,0.4), the distribution additionally skews to the left, 





In addition to shape, we also explore the assumption that the KD distribution is 
continuous everywhere. Whereas this assumption is credible near the distribution mean 
where the frequency of molecules is sufficiently high, we expect it to fail at the extreme 
tails where stochastic effects dominate and highly specific sequences can create gaps in 
the affinity distribution. Indeed, it is well-known that even single base-pair changes in 
DNA can dramatically impact binding (30). Ligands in this regime are highly prized, but 
may also be at highest risk to be lost to stochastic effects due to low copy numbers. 
We investigate this risk by using an initial N(−4,0.4) distribution and adding a 
fixed noise component that is randomly sampled from a uniform distribution in log-
space. Fig. 2.3 and Movie S1 show a comparison of 2 Monte Carlo simulations where 
there are only 20 ligands present in the range of KD<10−7M, i.e., where the continuous 
Gaussian distribution is effectively zero. We find that random binding effects can lead to 
total loss of those 20 ligands, resulting in a very different evolution of the KD distribution 
from cycle 12 onward in comparison with the case where only 2 of those ligands survive. 
SI, Fig. 2.S2 shows a distribution of the mean ligand KD at cycle 20 obtained from 250 
Monte Carlo simulations, confirming this enormous variability in outcomes, where the 
mean KD value spans 3 orders of magnitude. 
These results demonstrate the tremendous sensitivity of selection dynamics to 
both distribution shape and noise. They illustrate that selection pressures are 
parameterized not only by extrinsic environmental conditions given by the experimental 




uncertain intrinsic population parameters that govern relative competition between 





Figure 2.3: Noise affects SELEX dynamics.  
We fix the experimental parameters, the initial Gaussian distribution N(−4,0.4) and the 
added noise of only 20 additional ligands initially present between KD=10−10M and 
5×10−8M. Two different Monte Carlo simulations from these identical initial conditions 
show dynamics of selection under random loss of the 20 strongest binders (blue 
triangles), versus dynamics when only two of those strong binders with affinities between 
10−10 and 10−9M are selected (red dots). In the latter case, these two high-affinity binders 
completely dominate the distribution from cycle 12 on and outcompete the remaining 




Revising Target Concentration 
Optimization of the target concentration, Ttot, has long stood as a critical step in 
adjusting selection pressure based on experimental parameters (14–16). However, the 
results from the previous section now suggest that in addition to these experimental 
factors, the intrinsic affinity distribution of the initial ligand pool may have a significant 
influence on the impact Ttot exerts on the overall selection pressure. In light of this, we 
revisit the topic to study this impact by varying both Ttotand the initial distribution. Fig. 
2.4 and Movie S2 first show the dramatic impact of target concentration on selection 
dynamics. The results indicate that Ttot=10−4M (blue) provides optimal selection out of 
the three investigated target concentrations that use the initial Gaussian distribution 
N(−4,0.4). To investigate the impact of Ttot more systematically, Fig. 2.5 shows the mean 
KD value of ligands selected after 20 cycles as a function of Ttot for 9 different initial 
distributions. Note that as the mean KD decreases, the average binding strength of the 
pool increases. Fig. 2.5 confirms that intermediate values of Ttot yield optimal selection. 
SI, Fig. 2.S7 A–C further shows that adding noise to the initial distributions introduces 
additional variability, but provides similar qualitative results. Interestingly, we find that 
different initial distributions can have very different optimal Ttot, stressing the importance 
of devising a strategy to mitigate this impact and thereby control the inherent uncertainty 





Figure 2.4: Impact of target concentration on SELEX dynamics.  
Evolution of KD distribution for three different values of the target concentrations is 
shown. Under a high target concentration of Ttot=10−2M, the distribution shifts to the left 
and narrows, but does not skew toward high-affinity ligands. Additional skewing is 
achieved by reducing to Ttot=10−4M, which increases selection pressure by intensifying 
ligand competition. However, further reduction to Ttot=10−8M has the opposite effect and 
actually halts selection. In this case, the target concentration is so low that nonspecific 






Figure 2.5: Optimal target concentrations strongly depend on assumed initial KD 
distribution.  
The plot shows the mean KD as a measure of pool binding strength for the SELEX pool at 
cycle 20 using different constant target concentrations. Depending on the initial 
distribution of ligands, we find vastly different optimal target concentrations, i.e., 




KS dependence and nonspecific selection  
Our hybrid model has allowed us to explore the impact of the unknown initial KD 
distribution and the target concentration Ttot, which are both present in all SELEX 
protocols. However, our model additionally introduces a ligand–substrate interaction that 
has never before been studied and offers a unique opportunity to apply it toward more 
recent selection schemes aimed at small-molecule aptamer development (26–28). We 
therefore extend our analysis to study uncertainties that govern an optimum KS, and 
observe how changes in KS impact selection dynamics for different KD distributions. 
Fig. 2.6 and Movie S3 show the evolution of a single initial KD distribution for 
three different values of KS, showing an optimal outcome for KS =10−12M (blue). Noting 
these dynamics, we next vary KS systematically and observe the mean KD value of 
ligands present at cycle 20 for 9 different initial KD distributions (Fig. 2.7 and SI, 2.S7 
D–F). Similar to target concentration, we find an optimum in the intermediate ranges of 
KS and a clear dependence on the initial distribution. However, contrary to target 
concentration, the mean KD for smaller KS is relatively insensitive. Thus, these results 
suggest that a lower value of KS =10−16M would provide similar results across a 
multitude of initial distributions. 
As it pertains to small-molecule selection schemes, these results provide useful 
insights into the impact that substrate binding affinity has on selection efficiency, and 
may offer some guidance in the appropriate selection of a substrate material. The results 
also provide general insights into the impact of partitioning efficiency and nonspecific 




partitioning efficiency or fraction of nonspecific selection can impact different initial 





Figure 2.6: Impact of KS on SELEX dynamics. 
The plot shows the evolution of KD distribution for three different values of KS . Similar 
to target concentration, we find an optimal outcome in the middle range (KS =10−12M, 
blue), but the outcome for low KS is not as adverse as for low Ttot, because the 





Figure 2.7: Optimal KS depends on initial distribution.  
Plot of mean KD for the SELEX pool at cycle 20 using different values of KS . Reducing 
KS from its optimal value does not increase the mean KD as strongly as a reduction of the 




Improving selection efficiency 
 
We have shown that the initial KD distribution has a tremendous impact on 
selection efficiency and plays a significant role in modulating the impact of experimental 
parameters such as Ttot and KS. These results highlight that whereas established protocols 
are expected to perform well for some distributions, they may perform moderately for 
others. To address this variability in outcomes, we finally explore strategies to mitigate 
these impacts using only the experimental parameters Ttot and KS. As a metric for our 
analysis, we introduce the quantity ϕ(c), which describes the fraction of ligands with KD 
<10−10M at cycle c={1,…,C}. Using this quantity, we further introduce two measures of 
efficiency: success probability Φ=ϕ(C) and success speed SC defined as the cycle c at 
which ϕ(c)=0.5ϕ(C). 
We have seen that KS and Ttot play distinct roles in the evolutionary dynamics of 
the KD distribution. However, both parameters exhibit regimes of optimal selection that 
depend heavily on the initial distribution mean and width. Figs. 2.5 and 2.7 show that 
high values for Ttot and KS have a similar impact across all distributions, and suggest a 
conservative approach of beginning at these high values for the initial cycles. This 
reduces the risk of eliminating high-affinity, low copy number ligands early on. As these 
high-affinity ligands are amplified in subsequent rounds, Ttot and KS can be lowered to 
rapidly eliminate the remaining low-affinity ligands (SI, Figs. 2.S3 and 2.S4). Whereas 
ideas to lower the target concentrations have been discussed previously (26), our results 
indicate that other parameters such as KS can be tuned simultaneously to improve 




shows Φ and SC obtained from 50 Monte Carlo simulations of an improved protocol 
where both Ttot and KS are decreased over the cycles as described in SI Appendix, Table 
2. These results are compared with the original protocol with constant values Ttot=10−4M 
and KS=10−12M (26); SI, Fig. 2.S5 shows ϕ(c) including the SDs. Using six different 
initial Gaussian distributions with noise added similar to Fig. 2.3, we observe that the 
improved protocol with decreasing Ttot and KS is faster and leads to a higher fraction of 
high-affinity binders than the original protocol. As an alternative metric of protocol 
performance, SI, Fig. 2.S8 shows the evolution of mean KD across the cycles, and also 
introduces two alternative protocols where Ttot or KS are decreased faster than in the 
improved protocol. The results indicate that whereas faster decreases can further improve 






Figure 2.8: Plots comparing the fraction of high-affinity ligands Φ and speed of 
SELEX for six different KD distributions. 
The values are obtained from averaging 50 Monte Carlo simulations. We observe that 
decreasing Ttot and KS over the rounds will lead to a higher fraction of strong binders 







The results of our modeling draw striking parallels to outcomes in evolutionary 
biology, where environmental parameters define a fitness landscape and competition can 
change this landscape to influence survival and reproduction (31). Within SELEX, 
ligands compete for target molecules to ensure survival into the next cycle, whereas 
substrate binding traps the ligands and leads to their removal. Reduction of target 
concentration can increase competition, but when few target molecules are present, even 
high-affinity binders are unlikely to find a target. Similar to competition in limited 
resources scenarios, we find that the chance of survival for even the highest affinity 
ligand strongly depends on the strengths of the other ligands present in the population. 
Our surprising finding that a handful of high-affinity ligands can outcompete a pool of 
1015 ligands is also seen in evolutionary biology, where highly advantageous traits can 
quickly spread in a population, given the right conditions. The model enables one to 
identify the parameters impacting selection, and can thus be used to improve selection 
efficiency. A further important component of evolution in biological systems is 
mutations. Mutations in SELEX can also appear during PCR amplification, but usually 
lead to reduced affinities of the strongest aptamers (30), so we ignored them in our 
current approach. However, for some SELEX protocols, mutations can be beneficial to 
expand the experimental sampling space (32), and it may be interesting to extend our 





In summary, our model provides a better understanding of the impact of the 
uncertainties in SELEX, and how experimental parameters can be tuned to improve 
outcome and speed of this expensive and time-consuming protocol. We have 
demonstrated how optimization of the parameters can enhance selection efficiency of one 
protocol dramatically, and we envisage that simple adaptations of our model can be used 
to improve the many other established protocols, as well as guide the design of novel 







Table 2.S1: Default parameters. 
 
Table 2.S2: The improved protocol. 
 
 
Table 2.S3: Alternative protocols used in Fig. S8. 
The fast KS decrease protocol decreases Ttot similarly to the improved protocol, but KS is 
decreased faster through the cycles. Likewise, the fast Ttot decrease protocol decreases KS 





Figure 2.S1: SELEX dynamics over 20 cycles for six initial KD distributions: four 
Gaussians with different means and standard deviations, an exponential 
distribution, and one uniform distribution. 
While we certainly would not expect the real KD distribution for targets of interest to be 
exponential or uniform, it is interesting to see the dynamics of SELEX for such 
distributions, and illustrates the point that the distribution has an important influence on 
selection efficiency. We see that the dynamics of evolution is quite different: in the 
uniform case, due to the large number of good binders, the bad ones are quickly removed. 
The exponential distribution (e) or the broad Gaussian (d) guarantee a sufficient number 
of good binders being present, but the protocol is not able to magnify the best binders 
(here, KD = 10-12M) and slightly worse binders still form the peak of the distribution. On 
the other hand, for the Gaussians (a)-(c), the protocol quickly selects the best binders 





Figure 2.S2: Plot showing the distribution of the mean KD of aptamers present after 
cycle 20 for the same experimental condition presented in Fig 2.3.  
The distribution reflects results from 250 identical Monte Carlo simulations. 
 
 
Figure 2.S3: Snapshots of the fraction of high-affinity aptamers with binding 
affinities stronger than KD = 10-10 M. 
(a) At cycle 8, target concentrations close to 10-6 are the first to yield an increase of high 
affinity aptamers, and faster decreases broaden the range of target concentrations that 
lead to strong binders. (b) At cycle 20, a wide range of target concentrations leads to 




concentrations (Ttot>10-1M)) can still lead to success, provided the concentration is 
decreased sufficiently fast. 
 
 
Figure 2.S4: Snapshots of the fraction of high-affinity aptamers with binding 
affinities stronger than KD = 10-10 M at two different cycles as a function of initial 
KS. 
(a) At cycle 8, lower initial values of KS result in faster enrichment of high affinity 
aptamers. (b) At cycle 20, most initial values of KS eventually lead to enrichment of high-





Figure 2.S5: Fraction of high affinity binders at each cycle.  
Comparison of SELEX dynamics between the original SELEX protocol (Table S1 with 
constant Ttot and KS, and the improved protocol with decreasing target concentration and 
KS for six different Gaussian distributions with means -3,-4,-5 and standard deviations 
0.4, 0.8. Plot shows fraction of good binders (binding stronger than 10-10	M over SELEX 
cycles and the standard deviation observed over 50 Monte Carlo simulations. We notice 
that the improved case reaches higher or equal plateaus as the constant protocol, and it 
reaches the plateau much faster. There is less variability in the success measures when 
the initial Gaussian is broader, as in those cases there is initially a large number of good 





Figure 2.S6: Threshold dependence.  
We show the dependence of simulation results on the threshold that defines when we use 
the stochastic or the deterministic model. In each case the initial distribution is a 
Gaussian N(-4,0.4) with added noise. (a) and (b) show sample realization for threshold=0 
and threshold=1000. The case of threshold=0 means that we always use the deterministic 
model. Thus, there is no loss of molecular species, and the handful of aptamers in the low 
KD range always outperform the ones with higher KD. The case for threshold =1000 does 
appear qualitatively similar to the case threshold =100 used in the main text, so repeated 
runs are required to obtain statistical data. (c) and (d) show the dependence of the mean 
KD value, as a measure of protocol performance, for different values of threhsold. Each 
graph is obtained from averaging 150 Monte Carlo simulations and shown with the 
corresponding error bars. In (c), we notice no visible differences between thresholds 
between threshold=0 and threshold=1000 before cycle 10. This is because in those initial 
cycles, the randomness seen in low KD ligands does not affect the bulk of the ligand 
distribution, and thus does not affect the mean KD significantly. From cycle 10 on, the 
results of the non-zero thresholds deviate from the case threshold=0, which predicts 
lower mean KD values. This is because for deterministic dynamics, there is no loss of 
ligands possible throughout the cycles, and those high affinity ligands always take over 
the distribution after some time, as seen in (a). (d) shows the same data zoomed in, 
focusing on the non-zero thresholds from cycle 10 on. We see that from threshold =100 
to threshold =1000 there is no visible difference, justifying the choice of threshold =100 





Figure 2.S7: The dependence of the mean KD value on target concentration and 






Figure 2.S8: The mean KD of the distribution as a performance metric for the 
protocol is shown for 6 different initial Gaussian distributions with added noise, and 
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CHAPTER 3: Quantitative bioassay to identify antimicrobials through drug 
interaction fingerprint analysis 
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 Drug interaction analysis, which reports the extent to which the presence of one 
drug affects the efficacy of another, is a powerful tool to select potent combinatorial 
therapies and predict connectivity between cellular components. Combinatorial effects of 
drug pairs often vary even for drugs with similar mechanism of actions. Therefore, drug 
interaction fingerprinting may be harnessed to differentiate drug identities. We developed 
a method to analyze drug interactions for the application of identifying active 
pharmaceutical ingredients, an essential step to assess drug quality. We developed a 
novel approach towards the identification of active pharmaceutical ingredients by 
comparing drug interaction fingerprint similarity metrics such as correlation and 
Euclidean distance. To expedite this method, we used bioluminescent E. coli in a 
simplified checkerboard assay to generate unique drug interaction fingerprints of 
antimicrobial drugs. Of 30 antibiotics studied, 29 could be identified based on their drug 
interaction fingerprints. We present drug interaction fingerprint analysis as a cheap, 





Drug interactions for a given phenotype are defined as a combinatorial effect of 
two drugs that is different than expected(1). Drug interactions may be described as 
positive or negative depending on whether relatively more or less drug, respectively, is 
required to achieve a particular phenotype compared to single agents(1). Sensitive drug 
interaction testing is limited by the combinatorial explosion necessary to evaluate 
multiple doses of drugs. Traditional checkerboard testing involves isobologram analysis 
for a square matrix of increasing concentrations of two drugs on each axis. Berenbaum 
theorized a simplified method of testing for drug interactions in which approximately 
equi-inhibitory doses of two agents are combined, titrated and compared to single agent 
dose response curves(2).  
Drug interaction analysis is a powerful tool to select potent combinatorial 
therapies(3), predict connectivity between cellular components(4) and drug mechanism of 
action(5). Drugs with similar mechanism of action tend to have similar but not identical 
drug interaction profiles(6). For instance, Yeh et al. report that the two 30S ribosome 
inhibitors doxycycline and tetracycline cluster together in a network analysis based on 
their drug interaction profiles. However, amongst the 21 antibiotics they are tested 
against, they show unique interactions with ampicillin and chloramphenicol suggesting 
these varied combinatorial responses may be used to create a unique interaction 
fingerprint for these agents. A study of antifungal drug interactions found that two 
ergosterol synthesis (ERG11) inhibitors fluconazole and miconazole varied in their 




fingerprinting may be possible for any active pharmaceutical ingredient (API) that 
imparts a quantifiable phenotype such as luminescence or growth inhibition. 
A key feature of drug quality assessment is the detection of APIs. Current 
methods to detect APIs are of limited utility due to great expense (HPLC (8), NMR (9)), 
or low sensitivity/specificity (thin layer chromatography and colorimetric assays) of 
detection systems(10). These technologies are often of prohibitive cost, grid power and 
expertise to be of widespread use in low- and middle-income countries (LMICs). 
Biosensors may fill the gap for a fast drug detection system that transduces a change in 
growth phenotype to a specific change in luminescence output. Bacteria based biosensors 
are inherently reproducible and are low cost to maintain and propagate. The 
luminescence phenotype is especially desirable as it limits the possibility of false 
positives that may arise from contamination in assays evaluating turbidity. Previous 
bacterial biosensors have been used for the detection of antibiotic susceptibility in 
mycobacteria(11) and in drug mechanism of action studies by pharmaceutical 
companies(12). 
Approximately 25% of medicines in LMICs are counterfeit or substandard, the 
majority of which are antimicrobial agents13. Substandard medicines may contain 
impurities such as synthetic byproducts and degradation products or the wrong dose of 
active ingredient14. A recent survey of thousands of antimalarials, anti-mycobacterials 
and other antibiotics found 40% of sampled drugs failed quality testing in some world 
regions(15). This is of particular concern due to the high global burden of malaria and 




immediate concerns about treatment failures, substandard medicines are also 
hypothesized to contribute to the worldwide trend toward antimicrobial resistance 
(17,18). Successful treatment of tuberculosis requires months of medication, the mainstay 
of which is rifamycins (e.g., rifampicin, rifapentine, rifabutin), often in combination 
therapy with 2-3 other agents(19). Multidrug-resistant and extensively drug-resistant 
tuberculosis in particular necessitate prolonged combination therapy with up to 5 
medications(20). In 2014, there were an estimated 9.6 million new cases of tuberculosis, 
and 190,000 deaths due to multi-drug resistant tuberculosis(16). Novel means to address 
the issue of substandard medicines may therefore decrease the health and financial 
burden associated with long-term treatment of all forms of tuberculosis. 
In this study, we report a simplified checkerboard assay to quantify drug 
interactions between pairs of compounds in Escherichia coli expressing luciferase to 
expedite experiments. This methodology combines the sensitivity of larger checkerboard 
assays(1) to identify cellular response at varying levels of inhibition with the ease of 
setup of high throughput 2x2 drug interaction matrices by the Bliss independence model, 
which is a multiplicative model assuming drugs act independently. Using this method, we 
are able to generate unique profiles of bacterial response to varying combinations of 
drugs to create unique fingerprints for four anti-mycobacterial agents and a major 
rifampicin degradation product. By comparing drug interaction profile similarity metrics, 







Drug interaction profiling from a systematic screen of 25 antibiotics in E. coli 
In order to determine the feasibility of drug interaction profiling for API 
identification, we first analyzed a previously published dataset and unpublished data 
(literature set) of all pairwise interactions among 25 antibacterial drugs in E. coli for 
unique drug interaction profiles(21). Figure 1a illustrates the experimental and analytical 
system for assessing drug interactions with the checkerboard method. In this paradigm, 
drug interactions are scored based on the concavity of isophenotypic contours. Concavity 
is determined by the logit function: log(x/(1-x)) - log(y/(1-y)); where x and y are 
normalized drug concentrations to achieve a similar level of inhibition. Figure 1b shows a 
subset of interaction scores for two drugs tested against a panel of 25 antibiotics in 
replicate. Drug interaction fingerprints (or profiles) are defined as a series of drug 
interaction scores for each query drug tested against a set of array drugs. Drug interaction 
fingerprints can be utilized for drug identification if the same drug tested against an array 
of other drugs is more similar to biological replicates than to the profile of other drugs. 
We used Spearman’s correlation and Euclidean distance between profiles as a metric of 
similarity (Figure 3.1c).  
To account for systematic experimental biases, we created 1,000 sets of profiles 
(25x25x1000, per set) with randomized replicate order from the literature set. The 
randomized profiles were then compared to identify drug identity based on minimal 
Euclidean distance and maximum correlation between interaction scores in replicate 2 vs. 




replicate 2 scores of all 25 other agents. The most frequent replicate 2 ‘match’ of 1000 
randomizations was compared to replicate 1 identity to assess successful identification of 
API. Distance metrics alone could identify up to 8/25 antibiotics using drug interaction 
scores with a single drug partner (Figure 3.1d). Kanamycin, fusidic acid and 
erythromycin had the greatest single agent identification value (8,7,6 correct 
identifications, respectively). Starting with kanamycin, each of the remaining drugs was 
iteratively added to the analysis based on rank of single drug identification success. With 
all agents considered, 22/25 drugs were identified by distance alone (Figure 3.1e). 
Considering the entire dataset, the Spearman’s correlation between replicate profiles 
successfully identified 23/25 agents. A combined analysis of correlation and distance 
scores allowed the successful identification of all but one of the 25 drugs (spectinomycin 
incorrectly identified as chloramphenicol). However, spectinomycin ranked as the second 








Figure 3.1: Drug interaction profile based identification of antibiotics 
We first analyzed a previously published dataset of all pairwise interactions among 25 
antibacterial drugs in E. coli for unique drug interaction profiles21. Drug interactions were 
approximated by the concavity of isophenotypic contours in a 2D grid of linearly 
increasing drug concentrations on each axis (a). Positive interactions are represented in 
blue, negative in magenta. A subset of interaction score replicates for query drugs, 5-
fluorouracil and amikacin tested with array drugs chloramphenicol, ciprofloxacin, 
clarithromycin, erythromycin, fusidic acid and gentamicin (b). Drug interaction profiles 
are defined as a series of drug interaction scores for each query drug tested against a set 
of array drugs. Drug interaction profiles can be utilized for drug detection systems if the 
correlation of drug interaction profiles is greater for replicates than for comparison to 
other drug profiles (c). Alternatively, profile similarity may be based on minimum 
Euclidean distance between vectors of interaction. Euclidean distance between 
randomized replicates for query drugs against a single array drug could accurately 
identify 8/25 query drugs (d). Drugs were ranked based on their single agent 
identification value, serially added to the profile array and assessed for identification 
value based on Euclidean distance and/or rank correlation of profiles (e). Using the entire 
dataset, Euclidean distance, rank correlation and combined data could be used to 





A simplified sensitive method to assess drug interactions  
To expedite the construction of novel drug interaction profiles, drugs were 
evaluated based on the inhibition of luminescence of a constitutively expressed luciferase 
plasmid in E. coli. We used a simplified approach to the classic 8x8 checkerboard method 
of drug interaction by sampling 24 concentrations of single or combined drugs (Figure 
3.2a). An interaction score was computed based on the amount of drug mixture required 
to achieve 40% inhibition of luminescence compared to constituent drugs as single 
agents: log2(observed/expected dose) (Figure 3.2b). Positive and negative interactions 
indicate that relatively more or less drug respectively was required for the combination to 
achieve the same level of inhibition than expected based on constituent drugs and a score 




Figure 3.2: An expedited approach to drug interaction testing 
We used a simplified, yet sensitive, approach to the classic 8x8 checkerboard method of 
drug interaction by sampling 24 concentrations of single or combined drugs for inhibition 
of E. coli luminescence (a). Drug interactions were assessed based on the amount of drug 
mixture (1/2 each drug 1 and drug 2, relative to individual drug dose) required to achieve 
the same inhibitory level as the constituent drugs (2) for 40% inhibition of luminescence 
(IC40). Doses are plotted in Cartesian coordinates with the x and y intercepts set to drug 
1 and drug 2 IC40; the intersection of the line y=x and that connecting the two intercepts 
defines the expected IC40 of the combination (b). The interaction score is defined as 
log2(observed/expected distance from the origin). Deviations are classified as negative or 
positive interactions. Representative experiments for additive, positive and negative 
interactions (c upper, middle and lower panels, respectively). At left are plots of raw 
RLU over time superimposed on a heatmap of luminescence output. Luminescence 
output was defined as the area under the RLU curve normalized to the no drug condition. 
At right are plots illustrating expected (black dot) and observed (grey, cyan and magenta 
dots) doses of drug mixture required to achieve 40% inhibition of luminescence, based on 
drug 1 and drug 2 IC40 levels. CHL = chloramphenicol, DAP = dapsone, NIT = 
nitrofurantoin, RFQ = rifampicin quinone, MIX = mixture of drug 1 and drug 2.  




We validated our method by assessing the pairwise interactions between 5 query 
drugs and 8 array drugs. The 5 query drugs contained 4 anti-mycobacterial agents 
[dapsone, rifampicin, rifabutin, rifapentine] and one major degradation product of 
rifampicin [rifampicin quinone]. The array drugs consisted of antibiotics of varying 
mechanisms of action [chloramphenicol, erythromycin, mupirocin, nalidixic acid, 
nitrofurantoin, oxacillin, streptomycin, and tetracycline]. The query drugs were selected 
based on their significance in tuberculosis treatment; array drugs were selected to provide 
a diverse range of interactions. All query drugs were also tested in combination with each 
other. Interaction score biological replicates were highly reproducible (Spearman’s r = 
0.87, p = 5x10-16) (Figure 3.3a) and normally distributed (Figure 3.3b). Clustering 
analysis revealed that the rifampin related agents and degradation products had similar 
interaction profiles compared to the anti-folate agent dapsone (Figure 3.3c). Rifampin-
related drugs were enriched for antagonistic interactions (mean interaction scores, 0.47 - 
0.58) while dapsone was more likely to have negative or null interactions (mean 





Figure 3.3: Interactions of pairwise combinations of anti-mycobacterial and 
antibiotic drugs are highly reproducible 
Interaction score replicates for 50 drug pairs were highly reproducible (Spearman’s r = 
0.87, p = 5x10-16) (a) and normally distributed based on the one-sample Kolmogorov-
Smirnov test (b). The mean interaction score of all tested drug pairs (c). Clustering 
analysis reveals that dapsone had the most distinct interaction profile of all the query 
drugs, and rifapentine and rifabutin were most similar to each other. Of the rifampicin-
related compounds, rifampicin quinone had the least similar correlation of interaction 
profiles, suggesting that drug interaction profiling may be used to differentiate rifampicin 





Drug interaction profiling of anti-mycobacterial agents in E. coli 
In accordance with the literature set, drug profile similarity of the bioluminescent 
set was initially assessed by examining correlation and distance between 1,000 sets of 
randomized profile replicates (13x5x1000, per set). Array drugs varied greatly in their 
identification power for query drugs (Figure 3.4a). When only single drug interaction 
scores were considered among the profile, streptomycin was the drug with the best 
identification power (4/5 drugs identified accurately for the majority of 1,000 
randomizations). Nitrofurantoin and rifabutin had the next best identification power (3/5 
drugs each). The remainder of agents could be used to accurately identify up to 2 of the 5 
query drugs (Figure 3.4b). Dapsone, the only non-rifamycin agent tested, was 
unsurprisingly the simplest of the five query drugs to identify with 10/13 array drugs 
correctly identifying dapsone as single agents. For the majority of cases the rifampicin 
related drugs could be identified with 3-4 array drug data. In all, 4 array drugs were 
required to accurately discriminate between all 5 query drugs (Figure 3.4c). Perhaps due 
to the close relationship between the query drugs, correlation scores could at best identify 






Figure 3.4: Drug identification success among the bioluminescent set of anti-
mycobacterial agents 
Drug profile similarity was assessed by examining correlation and distance between 
1,000 sets of randomized profile replicates of the bioluminescent set. Array drugs varied 
greatly in their identification power for query drugs (a). Euclidean distance between 
randomized replicates for query drugs against a single array drug could accurately 
identify 4/5 query drugs (b) based on interactions with streptomycin alone. Drugs were 
ranked based on their single agent identification value, serially added to the profile array 
and assessed for identification value based on Euclidean distance and/or rank correlation 
of profiles (c). Using the entire dataset, Euclidean distance, rank correlation and 
combined data could be used to correctly identify all query drugs. Using more than 8 






The World Health Organization has increasingly recognized the role of 
counterfeit and substandard medicines in the emergence and spread of antimicrobial 
resistant diseases (22). Assuring drug quality of anti-mycobacterial agents has the 
potential to improve outcomes for the millions of people suffering from tuberculosis in 
LMICs worldwide. The current challenges in cost, training and infrastructure to assess 
drug quality requires novel approaches to identifying active pharmaceutical ingredients. 
Here, we utilized differential responses to drug combinations to create unique fingerprints 
for anti-mycobacterial drugs.  
We used bioluminescent E. coli to assess drug interactions between pairwise 
combinations of 5 anti-mycobacterial agents and 8 additional antibacterial drugs for a 
total of 50 drug pairs in replicate. Overall, this expedited approach to drug interaction 
testing was highly reproducible, retaining the ease of experimental setup normally 
associated with 2x2 dose combination matrices (6), while providing data for multiple 
levels of inhibition classically observable in checkerboard assays (23). The use of 
luminescence rather than turbidity as a proxy for cellular growth reduces experimental 
runtime from the typical 12-24 hours to one hour, which is more amenable to the quick 
assessment of drug quality. 
Biosensors have previously been shown to relay broad drug mechanism of action 
such as nucleic acid, cell wall or protein inhibition using luciferase and GFP reporters for 
drug target expression(12,24). These biosensors have utility in drug discovery and 




Drug interaction profiling can further narrow drug mechanism as drugs within the same 
class tended to cluster together, and unique drug interactions within classes can 
distinguish individual compounds.  
This technique should extend to any type of drug, so long as it elicits a 
quantifiable phenotype, such as luminescence. Although E. coli is in the phylum of 
Proteobacter while mycobacterium is in the phylum Actinobacteria, there is a large 
overlap in anti-mycobacterial agents and drugs that inhibit the growth of E. coli. In 
particular, RNA polymerase inhibiting drugs such as rifampicin, rifabutin and rifapentine 
are generally broad-spectrum antibiotics and therefore effective across a wide range of 
bacterial species (25,26). In our assay, E. coli are acting as a sensor and a one to one 
biological equivalent to mycobacteria is not essential for its utility in differentiating 
antimicrobial agents. However, not all anti-mycobacterial compounds affect E. coli 
growth. In such cases, the model organism M. smegmatis could be an alternative 
bacterium for creating drug interaction fingerprints (27). 
The analyses above suggest that interaction testing with only four array drugs are 
required to successfully identify the majority of query drugs from the literature and 
bioluminescent sets. Therefore, several unknown compounds could be identified on a 
single 96-well plate of interaction assays. Of all thirty query drugs evaluated in the 
literature and bioluminescent sets, only one could not be accurately identified based on 
the analytical methods described herein. The misattribution of chloramphenicol as 
spectinomycin suggests a high similarity between these two ribosome inhibitors. Our 




antimicrobial agents, even for highly similar agents such as rifampicin, rifabutin and 
rifapentine. Furthermore, this method could differentiate rifampicin from rifampicin 
quinone, which indicates that drug interaction profiling can be used to detect the presence 
of drug degradation products. 
A potential drawback of this approach may be the complexity of analyzing large 
drug-interaction datasets. This study used technologies such as a spectrophotometer and 
Matlab software for sensitive assessment of drug interactions. To convert this to a field 
test, photographic film may be used in lieu of a spectrophotometer to assess luminescence 
levels over time, and visual inspection can be used to verify if the drug interaction pattern 
matches the control drug. Alternatively, this assay could be adapted to a microfluidics 
based platform such as a lab in a suitcase (e.g., PharmaChk), which translates 
luminescence signal intensity to active pharmaceutical ingredient concentration (28). 
While this study evaluated 100 drug interactions overall to find unique drug 
interaction patterns among 5 query drugs, we found that as few as 4 array drugs are 
needed to differentiate even the highly similar rifamycin related compounds. Currently, 
there are approximately one hundred antibiotics that are in clinical use. Our study 
presented a quantitative bioassay to identify 30 antimicrobial drugs, which is a large 
subset of available medicines. Further studies could expand the repertoire of drug 
fingerprints, with prioritization given to other essential medicines that are most likely to 
be counterfeit or substandard. Thus, quantitative drug interaction profiling has the 





Systematic drug interaction profiling has many potential applications in drug 
discovery, mechanism of action and underlying cellular component connectivity. This 
manuscript presents the possibility of utilizing new drug interaction fingerprints in order 
to improve drug identification with applications in the detection of substandard and 
counterfeit medicines. Compared to the gold standard detection system of HPLC, our 
approach presents a fast, inexpensive and scalable method to assess drug quality.  
Materials and Methods 
Experimental conditions 
 Experiments were conducted with wild-type strain E. coli K12 strain DL41 with 
luciferase expressing SC101 plasmid(29). Luciferase expression showed that 
luminescence output is highly reproducible (Replicates of area under the luminescence 
curve were highly correlated (r = 0.99, p = 2x10-16) and well correlated with inoculum 
density (r =0.97, p = 8x10-7) (data not shown). All drugs were dissolved in DMSO and 
stored at −20°C. Bacterial cells were grown in LB liquid culture overnight and diluted 
1/100 for 1 hour before final plating on 96-well plates at a final OD600 of 0.05 in LB with 
the desired drug concentrations controlled for final solvent concentration of 2% DMSO at 
37°C. Plates were incubated in a temperature controlled microplate reader; with 
luminescence readings every 5 min. The following drugs were used in this study: 
chloramphenicol(CHL), dapsone (DAP), erythromycin (ERY), mupirocin (MUP), 
nalidixic acid (NAL), nitrofurantoin (NIT), oxacillin (OXA), rifabutin (RFB), rifapentine 





Drug interaction metrics 
Dose response was assessed for each single drug and combination (a one to one 
mixture) with linear dilutions. Drug combinations are an equal mixture of single agents 
containing approximately one half minimal inhibitory concentration of each single agent. 
Dose-response curves were generated based on the area under the luminescence curve, 
standardized to the drug free condition, over a one-hour interval. All doses are adjusted to 
fraction of minimal inhibitory concentration from zero to one.  
In Cartesian coordinates, the x and y intercepts are set to the concentration of drug 
1 and drug 2 to reach 40% inhibition of luminescence. The interaction score is defined as 
log2(observed/expected dose) along the y=x axis; where the expected is determined by 
the intersection of y=x with the line connecting the x and y intercepts and the observed is 
the dose of the drug mixture required to reach 40 % inhibition of luminescence (Figure 
2b). The same drug combined with itself is assumed to have zero interaction. 
Drug identification metrics 
 Drug interaction score replicates were randomized to generate 1000 sets of 
replicates in order to limit systematic experimental bias in the data (Figure 5). This 
translates to 2 sets of matrices of 25 query drugs x 25 array drugs x 1000 randomizations 
for the literature set, and 2 sets of matrices of 5 query drugs x 13 array drugs x 1000 
randomizations for the bioluminescent set. The Euclidean distance from each row of 
query drug data from set 1 to all other rows from set 2 was iteratively determined for all 
1000 randomizations. Overall, this generated a matrix of 25x25x1000 comparisons of 




set. A correct identification of the query drug was considered when the minimum 
Euclidean distance between each row in set 1 corresponded to the same row in set 2 (for 
example, rifabutin replicate 1 to rifabutin replicate 2). The same randomized datasets 
were assessed for the Spearman’s correlation between each row of set 1 and all rows in 
set 2. In this setup, a correct identification of the query drug was considered when the 
maximum correlation between each row in set 1 corresponded to the same row in set 2 
(for example, rifapentine replicate 1 to rifapentine replicate 2). Overall prediction success 
was determined by whether or not the correct query drug was identified by the mode of 
1000 predictions for Euclidean distance and Spearman’s correlation, respectively.  
For the combined analysis, drug interaction score replicates were randomized to 
generate 1000 sets of replicates to limit systematic experimental bias in the replicates. 
Euclidean distance and Spearman’s correlation were determined between all query drugs 
across replicates for all 1000 sets. For each set of replicates, the drug identification 
algorithm identified the query drug from replicate 1 with the minimum Euclidean 
distance as well as the maximum correlation with the query drug from replicate 2, for a 
total of 2000 predictions overall. A successful identification was based on whether the 




Figure 3.5: Workflow of drug interaction profile analysis. 
The entire matrix of drug interactions (50x25 for the literature set) was assigned to 
replicate 1 or 2. To eliminate systematic bias, the replicates were randomized. This 
translates to 2 sets of matrices of 25 query drugs x 25 array drugs x 1000 randomizations 
for the literature set. The Euclidean distance from each row of data from set 1 to all other 
rows from set 2 was iteratively determined for all 1000 randomizations. A correct 
identification of the query drug was considered when the minimum Euclidean distance 
between each row in set 1 corresponded to the same row in set 2 (for example, oxacillin 
replicate 1 ‘OXA1’ to oxacillin replicate 2 ‘OXA2’). The same randomized datasets were 
assessed for the Spearman’s correlation between each row of set 1 and all rows in set 2. 
In this setup, a correct identification of the query drug was considered when the 
maximum correlation between each row in set 1 corresponded to the same row in set 2. 
Oxacillin was nearly always identified by its drug interaction similarity by the correlation 
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CHAPTER 4: Evolution of rifampicin resistance due to substandard medicines 
 Abstract  
Poor-quality medicines undermine the treatment of infectious diseases such as 
tuberculosis, which requires months of treatment with rifampicin and other drugs. 
Rifampicin resistance is a critical concern for tuberculosis treatment. While sub-
therapeutic doses of medicine are known to select for antibiotic resistance, the effect of 
degradation products on the evolution of resistance is unknown. Here, we demonstrate 
that substandard medicines select for gene alterations that confer resistance to standard 
medicines. We generated drug resistant E. coli and M. smegmatis strains by serially 
culturing bacteria in the degradation product of rifampicin, rifampicin quinone. Strains 
resistant to rifampicin quinone developed cross-resistance to the standard drug 
rifampicin, with some populations showing no growth inhibition at maximum 
concentrations of rifampicin. Sequencing of the rifampicin quinone treated strains 
indicated that they acquired mutations in the DNA-dependent RNA polymerase B 
subunit. These mutations were localized in the rifampicin resistance clusters, consistent 
with other reports of rifampicin resistant E. coli and Mycobacteria. Rifampicin quinone 
treated mycobacteria also had cross-resistance to other rifamycin class drugs: rifabutin 
and rifapentine. Our results strongly suggest that substandard may actively contribute to 
the development of resistance to standard medicines for rifamycin class drugs.  
Introduction 
The ability to treat infectious diseases such as tuberculosis is an ongoing global 




over 300,000 of which are rifampicin or multi-drug resistant (1). Poor quality medicines 
undermine the treatment of infectious diseases (2). Substandard medicines vary from 
standard drugs due to poor formulations associated with incorrect dose or bioavailability, 
or due to post manufacturing issues such as drug expiration and improper storage 
conditions (3, 4). Antimicrobial agents are among the most prevalent drugs to be 
counterfeit or substandard (3).  
Drug degradation products may partially or fully replace the standard active 
pharmaceutical ingredient, resulting in a diminished dose to patients (5). Such under-
dosing regimens are associated with the evolution of antimicrobial resistance (6). 
Therefore, substandard medicines are hypothesized to be a contributory factor in the 
worldwide trend towards antibiotic resistance. However, whether bacterial exposure to 
drug degradation products may cause the evolution of resistance to standard antibiotics 
has not been previously studied. 
Rifampicin is a broad-spectrum rifamycin-derived antibiotic that is the basis of 
anti-tuberculosis monotherapy and combination treatment regimens (7). Of 10 million 
new TB cases in 2016, 600,000 were rifampicin resistant, necessitating the use of 
secondary treatments with increased toxicity (1, 8, 9). Rifampicin may also be used as a 
prophylaxis against staphylococcal and meningococcal infections, and has efficacy 
against a broad range of pathogens including E. coli and pseudomonas. Clinically, 
resistance may arise from drug regimen adherence issues and inappropriate treatments 
(10). In vitro studies demonstrate that subinhibitory doses of drugs may select for 




The drug target of rifampicin is the rpoB subunit of DNA-dependent RNA 
polymerase (12). Resistance to rifampicin predominately arises due to mutations in the 
rpoB gene (13), resulting in a decreased affinity of rifampicin to its binding site (14). 
Three noncontiguous regions of the rpoB gene have been recognized as resistance 
clusters due to the high frequency of mutations at these sites in samples of drug resistant 
pathogens. Even single amino acid changes in the resistance clusters may confer a high 
degree of resistance.   
Poorly synthesized or improperly stored rifampicin may contain impurities and 
degradation products (15). Rifampicin’s main degradation product occurs from non-
enzymatic auto-oxidation to form rifampicin quinone (16). The presence of rifampicin 
quinone in rifampicin containing tablets is a marker of poor quality (17). Rifampicin 
quinone may cause immunosuppression in animal models (18) and may underlie 
rifampicin-associated adverse drug interactions (19, 20). 
The phenomenon of cross-resistance occurs when bacteria gain resistance to an 
antibiotic it has not been exposed to after gaining resistance to another antibiotic (21). 
Cross-resistance is common among antibiotics from similar classes; for example, Oz et 
al. reported cross-resistance between 3 DNA gyrase inhibitors in E. coli independently 
cultured under a single drug condition (22). Therefore, bacteria may be expected to 
acquire resistance to a standard antibiotic after exposure to a structurally similar drug 
degradation product.  
As a model of substandard medicines, we examine rifampicin resistance arising 




coli and M. smegmatis, the model organism for the study of M. tuberculosis. Here, we 
demonstrate that bacteria evolve resistance against both rifampicin and rifampicin 
quinone. Alarmingly, we found that bacteria that are resistant against the drug 
degradation product rifampicin quinone were also resistant to clinically relevant 
rifamycins. Our results strongly suggest that substandard medicines actively compound 
the worldwide antibiotic resistance problem by inducing the evolution of resistance to 
standard medicines.  
Materials and Methods 
Experimental conditions 
 Strains include wild type MG1655 Escherichia coli and MC(2) 155 
Mycobacterium smegmatis, cultured at 37C in LB media or Middlebrook 7H9 with ADC 
supplement plus 0.2% glycerol, respectively. Bacteria were grown in 2-fold increments of 
RIF or RFQ (Sigma), with the maximum concentration at 400 ug/mL, and a final solvent 
concentration of 2% DMSO. We selected the bacteria in the well closest to MIC/2 to seed 
new bacterial cultures on the same dose series of RIF or RFQ after ~ 22 hours for E. coli 
and ~48 hours for M. smegmatis. Bacteria serially passaged in media plus 2% DMSO for 
the duration of the experiments served as the control groups.  
Genotyping of RNA polymerase B rifampicin resistance clusters 
Sequences were compared to the reference rpoB genes to for E. coli (NCBI gene ID: 
948488) and M. smegmatis (NCBI gene ID: 4535217), using ApE plasmid editing 




free LB agar plates and incubated at 37C overnight to isolate colonies for sequencing. 
The rifampicin resistance clusters of the rpoB gene was assessed by Sanger Sequencing 
(QuintaraBio) using the following primers.  
E. coli-rpoB-FWD 5’TCTCTGGGCGATCTGGATAC3’ 
E. coli-rpoB-REV 5’CAACAGCACGTTCCATACCA3’ 
M. smegmatis-rpoB-FWD 5’GCTGATCCAGAACCAGATCC 




We developed an in vitro model to examine the role of substandard medicines in 
the acquisition of rifampicin resistance. Similar to previous resistance evolution studies, 
we grew bacteria in increasing doses of rifampicin (RIF) or rifampicin quinone (RFQ) 
over time. For the initial experimental setup, the maximum dose was greater than the 
minimal inhibitory concentration (MIC) for these compounds. We selected the bacteria in 
the well closest to MIC/2 to seed new bacterial cultures on the same dose series of RIF or 
RFQ (Methods). In such a setting, bacteria are expected to have a higher likelihood of 
resistance conferring mutation than in the drug free or very low drug condition, and the 
IC50 is expected to increase over time (22). We first studied E. coli, gram-negative 
bacteria with a short doubling time and evaluated its dose response to RIF or RFQ in 1-
day cycles. We evolved resistance to RIF or RFQ, in three biological replicates. After 
only five cycles of selection, we observed resistance in all the strains, ranging from 2-fold 




as RIF-res 1 to 3 and RFQ-res 1 to 3 and prepared glycerol stocks for further 
experimentation. These stocks were grown in cultures without selective pressure in drug-
free media prior to follow up studies.  
 
Figure 4.1: Evolution of resistance in E. coli exposed to rifampicin or the drug 
degradation product rifampicin quinone  
E. coli are cultured in an array of concentrations of either rifampicin (a) or the drug 
degradation product rifampicin quinone (b) with 2-fold increments of doses. Each day, 
bacteria are selected from the dose at approximately one half the minimal inhibitory 
concentration (MIC/2) (red circles), diluted in fresh media and are aliquoted to a fresh 
array of drugs. All experiments were conducted in triplicate, with each heatmap 
corresponding to the top dose response curves in the subplots at right. The right shift in 
dose response curves over time demonstrates that E. coli acquire up to 14-fold increase in 
MIC after exposure to rifampicin (a) and 32-fold increase in MIC after exposure to 





RIF-resistant E. coli strains retained their increased MIC to RIF, confirming that 
these strains have acquired stable resistance (Figure 4.2a). Next, we wondered whether 
RFQ-resistant strains would be resistant to rifampicin. To answer this question, we grew 
our RFQ-res strains in increasing doses of RIF (Figure 4.2b). E. coli cultured in the drug 
degradation product rifampicin quinone reached up to 64-fold increase in resistance to 
rifampicin compared to solvent treated controls, despite no previous exposure to the 
standard drug. The level of rifampicin resistance was also higher in RFQ-res vs RIF-res. 
This result provides a proof of principle that substandard antibiotics may confer 
resistance to standard antibiotics.  
We evaluated all three RIF-res and three RFQ-res populations for mutations in the 
rifampicin resistance cluster of the rpoB gene (Methods). Two of the RIF-res strains had 
non-synonymous mutations in rifampicin-resistance clusters (Figure 4.2c). Remarkably, 
all of the RFQ-res strains had mutations in the rifampicin-resistance clusters, explaining 
their resistance to rifampicin. The cluster I mutation N518D was found in both RIF-res 
and RFQ-res populations, and has previously been associated with rifampicin resistant Tb 
(23). RFQ-res populations also had S512F and D516G mutations that have been 
previously reported in rifampicin resistant E. coli and Mycobacterium tuberculosis 
samples (s512f: (24); d516G: PMID: (25), (26)). The results suggest that substandard 
antibiotics may cause the selection of resistance to standard antibiotics via well-defined 





Figure 4.2: E. coli exposed to rifampicin or the drug degradation product rifampicin 
quinone show similar patterns of rifampicin resistance and genetic changes.  
E. coli resistant to either rifampicin (RIF-Res) or the drug degradation product rifampicin 
quinone (RFQ-Res) over 5 days were assessed for stable increase in rifampicin minimal 
inhibitory concentration, compared to solvent treated controls (wt). RFQ-Respopulations 
showed cross-resistance to rifampicin with up to 64-fold increase in IC50 (red circles). 
Each population was assessed for genetic changes in the rifampicin resistance region of 
the rpoB gene. The majority of populations that acquired resistance to either rifampicin or 
rifampicin quinone acquired non-synonymous mutations in the rifampicin resistance 
clusters of the rpoB gene, as denoted by the highlighted red amino acid. These mutations 






Rifampicin resistance is a critical concern for tuberculosis treatment. However, 
the long (~1 day) doubling time of Mycobacterium tuberculosis makes evolution 
experiments difficult to conduct. We therefore used M. smegmatis, a mycobacterium 
species with a shorter doubling time (2 hours), for our experiments. M. smegmatis cells 
were ~10-fold more sensitive to RIF and RFQ, compared to E. coli. Using the 
experimental setup described above, we evaluated M. smegmatis for the evolution of 
rifampicin resistance due to substandard medicines (Methods). We evolved six 
independent M. smegmatis strains resistant to RIF (names RIF-res1 to 6) and six strains 
resistant to RFQ (named RFQ-res1 to 6). Bacteria were selected from the dose that is 
closest to MIC/2, diluted in fresh media and aliquoted to a fresh array of drugs (Figure 
4.3), every 48-hours, for 11 cycles. After 22 days of serial passages, M. smegmatis 
exposed to rifampicin quinone drugs evolved an increase in MIC compared to solvent-
treated controls (t-test, p = 0.03), with population RFQ-res2 evolving up to 13-fold 
increase in MIC (Figure 4.3). We prepared glycerol stocks of all strains and used these 





Figure 4.3: Evolution of resistance in Mycobacteria exposed to rifampicin and the 
drug degradation product rifampicin quinone.  
M. smegmatis are cultured in an array of concentrations of either rifampicin (a) or the 
drug degradation product rifampicin quinone (b) with 2-fold increments of doses (n=6). 
Every 48 hours, bacteria are selected from the dose at approximately MIC/2 (red circles), 
diluted in fresh media and are aliquoted to a fresh array of drugs. Each heatmap 
corresponds to the upper left dose response curves. The right shift in dose response 
curves over time demonstrates that M. smegmatis acquired up to a 10-fold increase in 
MIC after exposure to rifampicin (b) and 13-fold increase in MIC after exposure to 






As expected, RIF exposed- M. smegmatis strains maintained resistance to 
rifampicin after culture in selection-free media, with MIC fold increase of 4 to 64-fold 
compared to the parental population (Figure 4.4a). We next evaluated if RFQ exposed M. 
smegmatis strains acquired resistance to RIF. We observed strong rifampicin resistance in 
four of these six strains. RFQ-res2 population acquired 128-fold resistance to RIF, 
despite being only exposed to RFQ.  
We assessed each population for genetic changes in the rifampicin resistance 
region of the rpoB gene. Three RIF-res populations and four RFQ-res populations 
acquired non-synonymous mutations in the rifampicin resistance clusters (Fig 4.4b). 
R529H (27), I572L (28) and P564L (29) mutations from RFQ-res M. smegmatis were 
previously reported in rifampicin resistant E. coli and mycobacteria. Therefore, we 
conclude that RFQ-exposure may select for genetic variants that are RIF-resistant in M. 
smegmatis.  
Cross-resistance is common between structurally similar compounds. Rifampicin 
is in the rifamycin class of antibiotics, with closely related drugs rifabutin (RFB) and 
rifapentine (RFP). RIF-res and RFQ-res populations were further tested for cross-
resistance to RFB and RFP (Fig 4.4c). Each of the RIF-resistant strains was resistant to 
both RFB and RFP, although resistance to RFB was only 2-fold in half of the 
populations. Half of the six RFQ-res populations had at least a 2-fold increase in the IC75 
to both RFB and RFP, despite never having been exposed to either of the compounds. 
RFQ-res2 strain, which had very high resistance to RIF, also had high resistance to RFB 




substandard medicines may acquire resistance to standard drugs with similar molecular 
structures.  
Figure 4.4: Mycobacteria exposed to rifampicin and the drug degradation product 
rifampicin quinone show similar patterns of rifampicin resistance and genetic 
changes. 
M. smegmatis resistant to either rifampicin (RIF-Res) or the drug degradation product 
rifampicin quinone (RFQ-Res) over 21 days were assessed for stable increase in 
rifampicin minimal inhibitory concentration, compared to solvent treated controls (wt) 
(a). RFQ-Res populations showed cross-resistance to rifampicin with up to 128-fold 
increase in IC75 (red circles). Each population was assessed for genetic changes in the 
rifampicin resistance region of the rpoB gene (b). Amino acid sequences of the rifampicin 
resistance clusters 1,2 and 3 are displayed, with amino acids numbered using the E. coli 
mapping notation. The displayed clusters are truncated to include regions with mutations 
in the evolved populations. The majority of populations that acquired resistance to either 
rifampicin or rifampicin quinone acquired non-synonymous mutations in the rifampicin 
resistance clusters of the rpoB gene. These mutations were consistent with previous 
reports of rifampicin resistance in M. tuberculosis and E. coli. Rifampicin resistant 
Mycobacteria also showed cross-resistance to other rifamycin drugs, rifabutin and 
rifapentine (c). Two RFQ-Res populations (RFQ-Res1 and 3) that did not have resistance 








According to the FDA, 10-25% of medicines worldwide are substandard (30), the 
majority of which are antimicrobial agents (2, 31). Up to one third of rifampicin 
containing medicines failed quality testing depending on world region (32-34). Despite 
these considerations, there has been no systematic study exploring the proximal and distal 
negative outcomes associated with substandard antimicrobial drugs. Apart from affecting 
the proximal treatment success of individual patients receiving subtherapeutic doses of 
medicine, it has been conjectured that substandard medicines affect treatment success in 
the future by promoting the evolution of resistance to standard medicines (35). 
In our study, we demonstrate that substandard medicines promote drug resistance 
through exposure to an agent similar to the standard drug. Bacterial strains quickly 
evolved resistance to the drug degradation product RFQ, and these strains were resistant 
to the standard drug RIF and two similar antibiotics RFB and RFP, despite never being 
exposed to any of these drugs. Gene analysis indicated that resistance to the substandard 
drug RFQ was often associated with mutations in the rifampicin resistance cluster, 
explaining the convergent evolution in RIF and RFQ conditions. Interestingly, the two 
RFQ-res mycobacteria strains that did not acquire resistance to rifampicin (RFQ-res1 and 
RFQ-res3) had cross-resistance to rifabutin. These strains had the same I572L mutation 
in the rpoB gene. One of the RFQ treated mycobacterial populations became highly 





E. coli acquired rifampicin resistance more quickly than M. smegmatis. This could 
be due to the differences in doubling time between the two organisms. E. coli populations 
double in approximately 20 minutes, while M. smegmatis populations double every 3 
hours. This translates to approximately twice as many doubling times for E. coli than M. 
smegmatis for the duration of experiments (5 days * 3 doublings/hour *24 h/day ~360 
doublings for E. coli. 21 days * 1 doubling/3 hours *24/day ~ 170 doublings for M. 
smegmatis).  
Rifampicin resistant tuberculosis is classically thought to arise through factors 
such as transmission, poor treatment adherence and immune status (36). Substandard 
medicines contribute to these factors by hindering efforts to control disease, and 
undermining patient trust in the medical system (10). This study demonstrates a direct 
link between rifampicin drug quality and the acquisition of antimicrobial resistance in 
two disparate bacterial species. It remains to be seen how these observations will translate 
to other substandard medicines. However, our study provides a proof-of principle 
strongly suggesting that substandard antibiotics affect not only the current treatment 
success, but also the future treatments by selecting for mutations that confer resistance to 
standard antibiotics.  
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CHAPTER 5: Discussion  
State of field before this work State of field after this work 
Computational models of aptamer 
selection strategies include varying 
drug target concentrations and 
partitioning efficiency 
Computational models of aptamer 
selection strategies evaluate the influence 
of varying drug target concentration and 
partitioning efficiency in the context of 
varying aptamer library affinity 
distributions 
Computational models of aptamer 
selection do not account for random 
loss of aptamers due to experimental 
conditions 
Computational model of aptamer 
selection considers the influence of 
random loss of aptamer on the probability 
of successful aptamer selection 
Biosensors can identify RNA 
polymerase targeting active 
pharmaceutical ingredients 
Biosensors can distinguish between 
different RNA polymerase targeting 
active pharmaceutical ingredients 
HPLC is required to resolve 
rifampicin from its degradation 
product rifampicin quinone 
Drug interaction fingerprints can 
differentiate rifampicin from its 
degradation product rifampicin quinone 
Subinhibitory doses of rifampicin are 
known to select for rifampicin 
resistance in Mycobacteria 
A rifampicin degradation product is 
shown to select for rifampicin resistance 
in Mycobacteria 
 
Table 5.1: State of the field before and after this dissertation 
 
 Among antimicrobial agents, anti-tuberculosis drugs such as rifampicin have a 
very high impact on global health given the annual incidence of tuberculosis is 
approximately ten million cases (1, 2). Antimicrobial resistance is a growing threat to the 
treatment of tuberculosis, with 200,000 deaths attributed to multidrug resistant 




both drug sensitive and drug resistance tuberculosis. This dissertation presents novel 
methodologies for detecting active pharmaceutical ingredients for drug quality assurance. 
Here, a computational model optimized the selection of aptamers to active 
pharmaceutical ingredients. As an alternative strategy, a bioassay was developed to create 
unique fingerprints for the detection of rifamycin-based drugs and the rifampicin 
degradation product rifampicin quinone. Finally, the data presented herein demonstrated 
that the drug degradation product rifampicin quinone contributes to rifampicin resistance 
in E. coli and the TB model organism Mycobacterium smegmatis via genetic changes in 
the DNA dependent RNA polymerase B subunit. 
Towards the aim of assessing selection strategies for DNA aptamers for small 
molecule drug detection, a computational model of SELEX was developed. This model 
provided a general framework that can be used to study the influence of experimental 
parameters on the probability of successful aptamer selection, including the affinity 
distribution of the aptamer library to the small molecule drug, affinity of the aptamer to 
the substrate used for partitioning drug-bound from drug-free aptamers, and 
concentration of small molecule drug target. This model also considered the influence of 
random events, which may lead to the loss of rare high affinity aptamers.  
This model demonstrated that very high and very low small molecule target 
concentrations could be prohibitive for aptamer selection, which is consistent with 
previous studies  (3). Under high target concentrations, selective pressure for a high 
affinity aptamer is low, so the affinity distribution changes little with each round of 




selection process as non-specific binding events predominate over specific aptamer to 
target binding. 
The probability of selecting a high affinity aptamer for a small molecule ligand is 
dependent on the initial KD distribution of the aptamer library. However, the KD 
distribution is uncertain. While many computational models for selection assume that the 
initial KD distribution is log normal (4-6), this model examined selection efficiency using 
both Gaussian and non-Gaussian distributions. This model determined that the presence 
of as few as 20 high affinity aptamers out of 1015 candidate aptamers could strongly 
influence selection efficiency. 
Similar to target concentration, intermediate ranges of affinity of aptamer to 
selection substrate are ideal for aptamer selection. Aptamer affinity to substrate may be 
tuned by increasing or decreasing the length of docking sequence for selection using 
capture oligonucleotides  (7). Aptamer affinity to the selection substrate can also be 
altered by utilizing novel substrate materials such as graphene oxide, which binds via pi-
pi interactions to single stranded DNA, and therefore preferentially adsorbs aptamers that 
are not bound to small molecule ligands  (8). Contrary to the use of very low small 
molecule target concentrations, the use of very high affinity substrate was still associated 
with successful aptamer selection under our model. High partitioning efficiency should 
decrease the nonspecific selection of low affinity aptamers. This is consistent with the 
findings of other SELEX simulations  (3, 4). 
Consistent with the findings of other research groups, high selection efficiency 




selection. While the initial affinity distribution of an aptamer library to a target is 
inherently unknown, previous studies tend to consider a single affinity distribution  (3, 4). 
The data presented here therefore simulated the influence of experimental conditions 
using a variety of potential affinity distributions. Another advantage of this model is that 
it considered the random loss of high affinity aptamers due to experimental conditions 
such as washing steps, or transfer of materials, which is more realistic than models that 
assume no loss of aptamer candidates over this multi-step and often months long set of 
experiments  (5). A limitation of this model is that it did not consider the impact of DNA 
mutations that may occur over rounds of selection on aptamer affinity to drug targets. 
Mutations may be detrimental if they eliminate high affinity aptamers. However they 
may be beneficial in increasing the diversity of aptamer candidates (9). Future versions of 
this model may therefore incorporate mutations to better understand its influence on the 
probability of selecting a high affinity aptamer. 
To determine whether anti-mycobacterial drugs may be identified based on drug 
interaction profiles in E. coli, differential responses to drug combinations in E. coli were 
used to create unique fingerprints for anti-mycobacterial drugs  (10). Novel drug 
interactions were assessed for 4 rifamycin based drugs and 1 drug degradation product 
against a panel of antibiotics with varying mechanism of action. By randomizing the data, 
de-identified vectors of drug interactions were compared to vectors of known drug 
interactions. The correct identification of active pharmaceutical ingredients was based on 
the similarity between drug interaction vectors, as measured by correlation and Euclidean 




Due to the high reproducibility of experiments and diversity of drug interactions, 
we were able to identify 29 of 30 antibiotics that were analyzed from both newly 
generated drug interaction profiles and from data obtained from the literature  (11). By 
utilizing luminescence instead of turbidity as a proxy for growth, experimental run time 
was reduced from approximately 1 day to 1 hour  (11, 12). Unlike HPLC, which is both 
resource and time intensive, many samples can be run in parallel for detection of active 
pharmaceutical ingredients. Furthermore, luminescence provides a simple signal for 
detection. While this study utilized a spectrophotometer, the method could be adapted for 
field-testing using photographic film and measurements of density or radius of signal as 
opposed to relative luminescence units  (13).  
In order to determine the fewest drug interaction experiments required to identify 
anti-mycobacterial query drugs, array drugs were ranked by their utility in distinguishing 
the five compounds of interest. Based on the interaction scores of streptomycin alone, 
four of the five query compounds could be confirmed. By adding in additional drug 
interaction data, all five compounds could be distinguished. As the remainder of drug 
interaction data was added to the analysis, the experimental noise among replicate 
interaction experiments was greater than the difference between query drugs; thereby 
weakening the ability to differentiate drugs by the fingerprinting method. This 
demonstrates that some of the array drugs serve as informers that are ideal for their 
distinct drug interactions among the query drugs. 
The drug interaction fingerprinting method sampled the checkerboard assay was 




combination as opposed to 64 concentration combinations  (14). The data analysis of this 
method is also relatively simple, by comparing relative doses to achieve different levels 
of inhibition as opposed to comparing the concavity of isophenotypic growth curves. By 
sampling several concentration combinations, this method is more robust than a 2x2 dose 
concentration setup that is sometimes used to measure drug combinatorial effect  (15).  
Systematic drug interaction profiling has many potential applications outside of 
drug quality assessment such as drug discovery and determination of mechanism of 
action  (16, 17). Previous studies used luciferase expressing B. subtilis to couple the 
detection of RNA polymerase targeting drugs with a luminescence signal (16, 18). The 
advantage of our method is the ability to distinguish between different drugs of the same 
class; in this case multiple rifamycin-derived drugs. This method is also capable of 
differentiating rifampicin from its primary degradation product, rifampicin quinone. 
Future studies may apply drug interaction based biosensors to differentiate drugs with 
other mechanisms of action. A limitation of this model is that not all anti-mycobacterial 
compounds affect E. coli growth. To extend this work to such drugs, the model organism 
M. smegmatis could be an alternative bacterium for creating drug interaction fingerprints  
(19).  
While this study provided predominately qualitative data on the presence or 
absence of a drug or degradation product, the data collected contains quantitative 
information on drug dose response. By simple adjustments to the drug-fingerprinting 
algorithm, query drug dose response could be compared to a reference drug dose 




to the calculation of the query drug concentration. This bioassay could therefore provide 
expedited information on both drug identity and concentration. 
A series of in vitro evolution experiments were conducted to determine whether 
exposure to rifampicin degradation products induces resistance to the standard 
antimicrobial rifampicin in E. coli and M. smegmatis. E. coli exposed to the degradation 
product rifampicin quinone developed over 50 fold resistance to rifampicin in under 1 
week. The development of resistance coincided with non-synonymous mutations in the 
rifampicin resistance cluster of the rpoB gene. M. smegmatis, acquired up to 100 fold 
resistance to rifampicin after exposure to rifampicin quinone for 21 days. Mycobacteria 
that were cultured in rifampicin quinone also acquired cross-resistance to the rifamycin 
drugs rifabutin and rifapentine. Many, but not all, of the M. smegmatis populations 
acquired mutations in the rpoB gene.  
A limitation of this study is that only the rifampicin resistance cluster region of 
the rpoB gene was sequenced. While no non-synonymous mutations were found between 
or flanking the clusters, it does not preclude mutations in other regions that may be 
associated with resistance. The vast majority of clinically derived rifampicin resistant 
mycobacterium tuberculosis strains have mutations in at least 1 of the 3 rifampicin 
resistance clusters, though mutations have also been reported in other regions of the gene  
(20, 21). Future studies may benefit from the sequencing of the entire rpoB gene. Whole 
genome sequencing would further allow for the detection of differential mutations under 




Nearly all the E. coli populations in the experimental set developed mutations in 
the rpoB resistance clusters, while 7/12 M. smegmatis populations had similar mutations. 
E. coli acquired rifampicin resistance more quickly than M. smegmatis. This could be due 
to the differences in doubling time between the two organisms. E. coli populations double 
in approximately 20 minutes, while M. smegmatis populations double every 3 hours. This 
translates to approximately twice as many doubling times for E. coli than M. smegmatis 
for the duration of experiments (5 days * 3 doublings/hour *24 h/day ~360 doublings for 
E. coli. 21 days * 1 doubling/3 hours *24/day ~ 170 doublings for M. smegmatis). E. coli 
and M. smegmatis have a mutation rate on the same order of magnitude: approximately 
10-10 mutations per nucleotide per generation  (22, 23). Future experiments may extend 
the number of serial passages to allow for equivalent generation time between organisms. 
An alternative explanation for some of the difference in resistance acquisition is the 
variation in genome size between the two organisms  (24). The M. smegmatis genome is 
approximately 1.5 times greater than E. coli’s genome with 6.99 x 106 and 4.64 x 106 
base pairs respectively. Few drug resistant strains are reported in organisms with very 
small genomes such as Mycoplamsa  (25). 
A limitation of this study towards understanding the etiology of drug resistance in 
tuberculosis is that experiments were conducted in vitro with the model organism M. 
smegmatis. Repeating the experiments with Mycobacterium tuberculosis would be more 
clinically relevant, though laborious to conduct and requiring Biosafety Level 3 
laboratories. In vivo testing in animal models may better recapitulate the etiology of 




Isoniazid is another important first-line anti-mycobacterial drug. Fixed dose 
combination capsules may contain substandard isoniazid due to poor manufacturing 
practices. Exposure to light, heat or humidity; acidic conditions may accelerate drug 
degradation  (26, 27). Isoniazid is a pro-drug that is activated by bacterial catalase-
peroxidase ‘KatG’. Isoniazid resistance is very common in clinical isolates and often 
associated with KatG of inhZ mutations  (25, 28). Therefore, repeating this experimental 
setup using isoniazid and its degradation products is a logical follow up to better 
understand mycobacterial resistance to the most important tuberculosis treatments. 
Overall, this research provides the first demonstration of mycobacterial rifampicin 
resistance due to exposure to a degradation product and presents a simple model for the 




Chapter 5 References 
1. World Health Organization (2017) Global tuberculosis report 2017, (World Health 
Organization, Geneva, Switzerland).  
2. World Health Organization (2014) Companion handbook to the WHO guidelines for 
the programmatic management of drug-resistant tuberculosis. 
3. Wang J, Rudzinski JF, Gong Q, Soh HT & Atzberger PJ (2012) Influence of target 
concentration and background binding on in vitro selection of affinity reagents. PLoS 
One 7(8): e43940. 
4. Chen C & Kuo T (2007) Simulations of SELEX against complex receptors with a 
condensed statistical model. Computers & Chemical Engineering 31(9): 1007-1019. 
5. Levine HA & Nilsen-Hamilton M (2007) A mathematical analysis of SELEX. 
Computational Biology and Chemistry 31(1): 11-35. 
6. Pressman A, Moretti JE, Campbell GW, Muller UF & Chen IA (2017) Analysis of in 
vitro evolution reveals the underlying distribution of catalytic activity among random 
sequences. Nucleic Acids Research 45(14): 8167-8179. 
7. Stoltenburg R, Nikolaus N & Strehlitz B (2012) Capture-SELEX: Selection of DNA 
aptamers for aminoglycoside antibiotics. Journal of Analytical Methods in Chemistry 
2012: 415697. 
8. Nguyen VT, Kwon YS, Kim JH & Gu MB (2014) Multiple GO-SELEX for efficient 
screening of flexible aptamers. Chemical Communications (Cambridge) 50(72): 10513-
10516. 
9. Hoinka J, et al (2015) Large scale analysis of the mutational landscape in HT-SELEX 
improves aptamer discovery. Nucleic Acids Research 43(12): 5699-5707. 
10. Weinstein ZB & Zaman MH (2017) Quantitative bioassay to identify antimicrobial 
drugs through drug interaction fingerprint analysis. Scientific Reports 7: 42644. 
11. Chandrasekaran S, et al (2016) Chemogenomics and orthology-based design of 
antibiotic combination therapies. Molecular Systems Biology 12(5): 872. 
12. Farha MA & Brown ED (2010) Chemical probes of escherichia coli uncovered 
through chemical-chemical interaction profiling with compounds of known biological 




13. Riska PF, et al (1999) Rapid film-based determination of antibiotic susceptibilities of 
mycobacterium tuberculosis strains by using a luciferase reporter phage and the bronx 
box. Journal of Clinical Microbiology 37(4): 1144-1149. 
14. Cokol M, et al (2014) Large-scale identification and analysis of suppressive drug 
interactions. Chemistry and Biology 21(4): 541-551. 
15. Yeh P, Tschumi AI & Kishony R (2006) Functional classification of drugs by 
properties of their pairwise interactions. Nature Genetics 38(4): 489-494. 
16. Urban A, et al (2007) Novel whole-cell antibiotic biosensors for compound 
discovery. Applied Environmental Microbiology 73(20): 6436-6443. 
17. Lehar J, et al (2007) Chemical combination effects predict connectivity in biological 
systems. Molecular Systems Biology 3: 80. 
18. Mariner KR, Ooi N, Roebuck D, O'Neill AJ & Chopra I (2011) Further 
characterization of bacillus subtilis antibiotic biosensors and their use for antibacterial 
mode-of-action studies. Antimicrobial Agents and Chemotherapy 55(4): 1784-1786. 
19. Gordon S, Parish T, Roberts IS & Andrew PW (1994) The application of luciferase as 
a reporter of environmental regulation of gene expression in mycobacteria. Letters in 
Applied Microbiology 19(5): 336-340. 
20. Campbell EA, et al (2001) Structural mechanism for rifampicin inhibition of bacterial 
rna polymerase. Cell 104(6): 901-912. 
21. Siu GK, et al (2011) Mutations outside the rifampicin resistance-determining region 
associated with rifampicin resistance in mycobacterium tuberculosis. Journal of 
Antimicrobial Chemotherapy 66(4): 730-733. 
22. Lee H, Popodi E, Tang H & Foster PL (2012) Rate and molecular spectrum of 
spontaneous mutations in the bacterium escherichia coli as determined by whole-genome 
sequencing. Proceedings of the National Academy of Sciences of the United States of 
America 109(41): E2774-83. 
23. Rock JM, et al (2015) DNA replication fidelity in mycobacterium tuberculosis is 
mediated by an ancestral prokaryotic proofreader. Nature Genetics 47(6): 677-681. 
24. Levy SB (2008) Genome size and antibiotic resistance. Antimicrobial Agents and 
Chemotherapy 52(7): 2696-07. 





26. Singh, S., Mariappan, T.T., Sharda, N.,Singh, B., (2000) Degradation of rifampicin, 
isoniazid and pyrazinamide from prepared mixtures and marketed single and combination 
products under acid conditions. Pharmacy and Pharmacology Communications 
Pharmacy and Pharmacology Communications 6(11): 491-494. 
27. Bhutani H, Mariappan TT & Singh S (2004) The physical and chemical stability of 
anti-tuberculosis fixed-dose combination products under accelerated climatic conditions. 
The international journal of tuberculosis and lung disease 8(9): 1073-1080. 
28. Banerjee A, et al (1994) inhA, a gene encoding a target for isoniazid and ethionamide 






Agrawal, S., Ashokraj, Y., Bharatam, P.V., Pillai, O. & Panchagnula, R. 2004, "Solid-
state characterization of rifampicin samples and its biopharmaceutic 
relevance", European journal of pharmaceutical sciences : official journal of the 
European Federation for Pharmaceutical Sciences, vol. 22, no. 2-3, pp. 127-144. 
Andres, S., Hillemann, D., Rusch-Gerdes, S. & Richter, E. 2014, "Occurrence of rpoB 
mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium 
tuberculosis isolates from Germany", Antimicrobial Agents and Chemotherapy, vol. 
58, no. 1, pp. 590-592. 
Arnold, A., Cooke, G.S., Kon, O.M., Dedicoat, M., Lipman, M., Loyse, A., Butcher, 
P.D., Ster, I.C. & Harrison, T.S. 2017, "Drug resistant TB: UK multicentre study 
(DRUMS): Treatment, management and outcomes in London and West Midlands 
2008-2014", The Journal of infection, vol. 74, no. 3, pp. 260-271. 
Asaumi, R., Toshimoto, K., Tobe, Y., Hashizume, K., Nunoya, K.I., Imawaka, H., Lee, 
W. & Sugiyama, Y. 2018, "Comprehensive PBPK Model of Rifampicin for 
Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction 
and OATP Inhibition Effects", CPT: pharmacometrics & systems pharmacology, . 
Ashokraj, Y., Kohli, G., Kaul, C.L. & Panchagnula, R. 2005, "Quality control of anti-
tuberculosis FDC formulations in the global market: part II-accelerated stability 
studies", The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease, vol. 9, 
no. 11, pp. 1266-1272. 
Baker, S. 2015, "Infectious disease. A return to the pre-antimicrobial era?", Science, vol. 
347, no. 6226, pp. 1064-1066. 
Ballereau, F., Prazuck, T., Schrive, I., Lafleuriel, M.T., Rozec, D., Fisch, A. & Lafaix, C. 
1997, "Stability of essential drugs in the field: results of a study conducted over a 
two-year period in Burkina Faso", The American Journal of Tropical Medicine and 
Hygiene, vol. 57, no. 1, pp. 31-36. 
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K.S., Wilson, T., 
Collins, D., de Lisle, G. & Jacobs, W.R.,Jr 1994, "inhA, a gene encoding a target for 
isoniazid and ethionamide in Mycobacterium tuberculosis", Science (New York, 




Basco, L.K., Ringwald, P., Manene, A.B. & Chandenier, J. 1997, "False chloroquine 
resistance in Africa", Lancet (London, England), vol. 350, no. 9072, pp. 224-
6736(05)62397-5. 
Bate, R., Jensen, P., Hess, K., Mooney, L. & Milligan, J. 2013, "Substandard and 
falsified anti-tuberculosis drugs: a preliminary field analysis", The international 
journal of tuberculosis and lung disease : the official journal of the International 
Union against Tuberculosis and Lung Disease, vol. 17, no. 3, pp. 308-311. 
Berenbaum, M.C. 1978, "A method for testing for synergy with any number of 
agents", The Journal of infectious diseases, vol. 137, no. 2, pp. 122-130. 
Berens, C., Thain, A. & Schroeder, R. 2001, "A tetracycline-binding RNA 
aptamer", Bioorganic & medicinal chemistry, vol. 9, no. 10, pp. 2549-2556. 
Bhutani, H., Mariappan, T.T. & Singh, S. 2004, "The physical and chemical stability of 
anti-tuberculosis fixed-dose combination products under accelerated climatic 
conditions", The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease, vol. 8, 
no. 9, pp. 1073-1080. 
Bhutani, H., Singh, S., Jindal, K.C. & Chakraborti, A.K. 2005, "Mechanistic explanation 
to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and 
isoniazid in anti-TB FDCs", Journal of pharmaceutical and biomedical 
analysis, vol. 39, no. 5, pp. 892-899. 
Blix, H.S., Viktil, K.K., Moger, T.A. & Reikvam, A. 2010, "Drugs with narrow 
therapeutic index as indicators in the risk management of hospitalised 
patients", Pharmacy practice, vol. 8, no. 1, pp. 50-55. 
Bolt, H.M. & Remmer, H. 1976, "Implication of rifampicin-quinone in the irreversible 
binding of rifampicin to macromolecules", Xenobiotica; the fate of foreign 
compounds in biological systems, vol. 6, no. 1, pp. 21-32. 
Caminero, J.A. 2008, "Likelihood of generating MDR-TB and XDR-TB under adequate 
National Tuberculosis Control Programme implementation", The international 
journal of tuberculosis and lung disease : the official journal of the International 
Union against Tuberculosis and Lung Disease, vol. 12, no. 8, pp. 869-877. 
Campbell, E.A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. & 
Darst, S.A. 2001, "Structural mechanism for rifampicin inhibition of bacterial rna 




Castan, P., de Pablo, A., Fernandez-Romero, N., Rubio, J.M., Cobb, B.D., Mingorance, J. 
& Toro, C. 2014, "Point-of-care system for detection of Mycobacterium tuberculosis 
and rifampin resistance in sputum samples", Journal of clinical microbiology, vol. 
52, no. 2, pp. 502-507. 
Chandrasekaran, S., Cokol-Cakmak, M., Sahin, N., Yilancioglu, K., Kazan, H., Collins, 
J.J. & Cokol, M. 2016, "Chemogenomics and orthology-based design of antibiotic 
combination therapies", Molecular systems biology, vol. 12, no. 5, pp. 872. 
Chen, C. & Kuo, T. 2007, "Simulations of SELEX against complex receptors with a 
condensed statistical model", Computers & chemical engineering, vol. 31, no. 9, pp. 
1007-1019. 
Cherney, L.T., Obrecht, N.M. & Krylov, S.N. 2013, "Theoretical modeling of masking 
DNA application in aptamer-facilitated biomarker discovery.", Analytical 
Chemistry, vol. 85, no. 8, pp. 4157-4164. 
Coker, C., Zhao, H. & Mobley, H.L. 2002, "Green fluorescent protein urea sensors. 
Uropathogenic Proteus mirabilis", Methods in molecular biology (Clifton, N.J.), vol. 
183, pp. 287-293. 
Cokol, M., Chua, H.N., Tasan, M., Mutlu, B., Weinstein, Z.B., Suzuki, Y., Nergiz, M.E., 
Costanzo, M., Baryshnikova, A., Giaever, G., Nislow, C., Myers, C.L., Andrews, 
B.J., Boone, C. & Roth, F.P. 2011, "Systematic exploration of synergistic drug 
pairs", Molecular systems biology, vol. 7, pp. 544. 
Cokol, M., Weinstein, Z.B., Yilancioglu, K., Tasan, M., Doak, A., Cansever, D., Mutlu, 
B., Li, S., Rodriguez-Esteban, R., Akhmedov, M., Guvenek, A., Cokol, M., Cetiner, 
S., Giaever, G., Iossifov, I., Nislow, C., Shoichet, B. & Roth, F.P. 2014, "Large-
scale identification and analysis of suppressive drug interactions", Chemistry & 
biology, vol. 21, no. 4, pp. 541-551. 
David, H.L. 1970, "Probability distribution of drug-resistant mutants in unselected 
populations of Mycobacterium tuberculosis", Applied Microbiology, vol. 20, no. 5, 
pp. 810-814. 
Durao, P., Guleresi, D., Proenca, J. & Gordo, I. 2016, "Enhanced Survival of Rifampin- 
and Streptomycin-Resistant Escherichia coli Inside Macrophages", Antimicrobial 
Agents and Chemotherapy, vol. 60, no. 7, pp. 4324-4332. 
Ellington, A.D. & Szostak, J.W. 1990, "In vitro selection of RNA molecules that bind 




Fan, J., de Jonge, B.L., MacCormack, K., Sriram, S., McLaughlin, R.E., Plant, H., 
Preston, M., Fleming, P.R., Albert, R., Foulk, M. & Mills, S.D. 2014, "A novel high-
throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in 
bacteria", Antimicrobial Agents and Chemotherapy, vol. 58, no. 12, pp. 7264-7272. 
Farha, M.A. & Brown, E.D. 2010, "Chemical probes of Escherichia coli uncovered 
through chemical-chemical interaction profiling with compounds of known 
biological activity", Chemistry & biology, vol. 17, no. 8, pp. 852-862. 
Farha, M.A., Czarny, T.L., Myers, C.L., Worrall, L.J., French, S., Conrady, D.G., Wang, 
Y., Oldfield, E., Strynadka, N.C. & Brown, E.D. 2015, "Antagonism screen for 
inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl 
diphosphate synthase", Proceedings of the National Academy of Sciences of the 
United States of America, vol. 112, no. 35, pp. 11048-11053. 
Farhat, M.R., Shapiro, B.J., Kieser, K.J., Sultana, R., Jacobson, K.R., Victor, T.C., 
Warren, R.M., Streicher, E.M., Calver, A., Sloutsky, A., Kaur, D., Posey, J.E., 
Plikaytis, B., Oggioni, M.R., Gardy, J.L., Johnston, J.C., Rodrigues, M., Tang, P.K., 
Kato-Maeda, M., Borowsky, M.L., Muddukrishna, B., Kreiswirth, B.N., Kurepina, 
N., Galagan, J., Gagneux, S., Birren, B., Rubin, E.J., Lander, E.S., Sabeti, P.C. & 
Murray, M. 2013, "Genomic analysis identifies targets of convergent positive 
selection in drug-resistant Mycobacterium tuberculosis", Nature genetics, vol. 45, 
no. 10, pp. 1183-1189. 
Frost, N.R., McKeague, M., Falcioni, D. & DeRosa, M.C. 2015, "An in solution assay for 
interrogation of affinity and rational minimer design for small molecule-binding 
aptamers", The Analyst, vol. 140, no. 19, pp. 6643-6651. 
Gordon, S., Parish, T., Roberts, I.S. & Andrew, P.W. 1994, "The application of luciferase 
as a reporter of environmental regulation of gene expression in 
mycobacteria", Letters in applied microbiology, vol. 19, no. 5, pp. 336-340. 
Gotrik, M., Sekhon, G., Saurabh, S., Nakamoto, M., Eisenstein, M. & Soh, H.T. 2018, 
"Direct Selection of Fluorescence-Enhancing RNA Aptamers", Journal of the 
American Chemical Society, vol. 140, no. 10, pp. 3583-3591. 
Greco, W.R., Bravo, G. & Parsons, J.C. 1995, "The search for synergy: a critical review 
from a response surface perspective.", Pharmacological reviews, vol. 47, no. 2, pp. 
331-385. 
Hall, Z., Allan, E.L., van Schalkwyk, D.A., van Wyk, A. & Kaur, H. 2016, "Degradation 
of Artemisinin-Based Combination Therapies Under Tropical Conditions", The 




Hansen, L.H. & Sorensen, S.J. 2000, "Detection and quantification of tetracyclines by 
whole cell biosensors", FEMS microbiology letters, vol. 190, no. 2, pp. 273-278. 
Hauck, Y., Fabre, M., Vergnaud, G., Soler, C. & Pourcel, C. 2009, "Comparison of two 
commercial assays for the characterization of rpoB mutations in Mycobacterium 
tuberculosis and description of new mutations conferring weak resistance to 
rifampicin", The Journal of antimicrobial chemotherapy, vol. 64, no. 2, pp. 259-262. 
Ho, N.T., Desai, D. & Zaman, M.H. 2015, "Rapid and specific drug quality testing assay 
for artemisinin and its derivatives using a luminescent reaction and novel 
microfluidic technology", The American Journal of Tropical Medicine and 
Hygiene, vol. 92, no. 6 Suppl, pp. 24-30. 
Hoinka, J., Berezhnoy, A., Dao, P., Sauna, Z.E., Gilboa, E. & Przytycka, T.M. 2015, 
"Large scale analysis of the mutational landscape in HT-SELEX improves aptamer 
discovery", Nucleic acids research, vol. 43, no. 12, pp. 5699-5707. 
Hong, H. & Park, W. 2014, "TetR repressor-based bioreporters for the detection of 
doxycycline using Escherichia coli and Acinetobacter oleivorans", Applied 
Microbiology and Biotechnology, vol. 98, no. 11, pp. 5039-5050. 
Horsburgh, C.R.,Jr, Barry, C.E.,3rd & Lange, C. 2015, "Treatment of Tuberculosis", The 
New England journal of medicine, vol. 373, no. 22, pp. 2149-2160. 
Ivask, A., Rolova, T. & Kahru, A. 2009, "A suite of recombinant luminescent bacterial 
strains for the quantification of bioavailable heavy metals and toxicity testing", BMC 
biotechnology, vol. 9, pp. 41-6750-9-41. 
Jähnke, R. & Dwornik, K. 2018, A concise quality control guide on essential drugs and 
other medicines: Supplement 2018 to Volume II on thin layer chromatography 
tests, GPHF, Frankfurt am Main, Germany. 
Jamieson, F.B., Guthrie, J.L., Neemuchwala, A., Lastovetska, O., Melano, R.G. & 
Mehaffy, C. 2014, "Profiling of rpoB mutations and MICs for rifampin and rifabutin 
in Mycobacterium tuberculosis", Journal of clinical microbiology, vol. 52, no. 6, pp. 
2157-2162. 
Jin, D.J. & Gross, C.A. 1988, "Mapping and sequencing of mutations in the Escherichia 
coli rpoB gene that lead to rifampicin resistance", Journal of Molecular Biology, vol. 
202, no. 1, pp. 45-58. 
Johnston, A. & Holt, D.W. 2014, "Substandard drugs: a potential crisis for public 




Kelesidis, T. & Falagas, M.E. 2015, "Substandard/counterfeit antimicrobial 
drugs", Clinical microbiology reviews, vol. 28, no. 2, pp. 443-464. 
Kenyon, T.A., Kenyon, A.S., Kgarebe, B.V., Mothibedi, D., Binkin, N.J. & Layloff, T.P. 
1999, "Detection of substandard fixed-dose combination tuberculosis drugs using 
thin-layer chromatography", The international journal of tuberculosis and lung 
disease : the official journal of the International Union against Tuberculosis and 
Lung Disease, vol. 3, no. 11, pp. 347-350. 
Kim, Y.S., Kim, J.H., Kim, I.A., Lee, S.J., Jurng, J. & Gu, M.B. 2010, "A novel 
colorimetric aptasensor using gold nanoparticle for a highly sensitive and specific 
detection of oxytetracycline", Biosensors & bioelectronics, vol. 26, no. 4, pp. 1644-
1649. 
Kishony, R. & Leibler, S. 2003, "Environmental stresses can alleviate the average 
deleterious effect of mutations", Journal of biology, vol. 2, no. 2, pp. 14-4924-2-14. 
Epub 2003 May 29. 
Koch, A., Mizrahi, V. & Warner, D.F. 2014, "The impact of drug resistance on 
Mycobacterium tuberculosis physiology: what can we learn from 
rifampicin?", Emerging microbes & infections, vol. 3, no. 3, pp. e17. 
Kohanski, M.A., DePristo, M.A. & Collins, J.J. 2010, "Sublethal antibiotic treatment 
leads to multidrug resistance via radical-induced mutagenesis.", Molecular cell, vol. 
37, no. 3, pp. 311-320. 
Konrad, P. & Stenberg, P. 1988, "Rifampicin quinone is an immunosuppressant, but not 
rifampicin itself", Clinical immunology and immunopathology, vol. 46, no. 1, pp. 
162-166. 
Kruse, A.J., Peerdeman, S.M., Bet, P.M. & Debets-Ossenkopp, Y.J. 2006, "Successful 
treatment with linezolid and rifampicin of meningitis due to methicillin-resistant 
Staphylococcus epidermidis refractory to vancomycin treatment", European journal 
of clinical microbiology & infectious diseases : official publication of the European 
Society of Clinical Microbiology, vol. 25, no. 2, pp. 135-137. 
Laserson, K.F., Kenyon, A.S., Kenyon, T.A., Layloff, T. & Binkin, N.J. 2001, 
"Substandard tuberculosis drugs on the global market and their simple 
detection", The international journal of tuberculosis and lung disease : the official 
journal of the International Union against Tuberculosis and Lung Disease, vol. 5, 





Lee, H., Popodi, E., Tang, H. & Foster, P.L. 2012, "Rate and molecular spectrum of 
spontaneous mutations in the bacterium Escherichia coli as determined by whole-
genome sequencing", Proceedings of the National Academy of Sciences of the 
United States of America, vol. 109, no. 41, pp. E2774-83. 
Lehár, J., Zimmermann, G.R., Krueger, A.S., Molnar, R.A., Ledell, J.T., Heilbut, A.M., 
Short, G.F., Giusti, L.C., Nolan, G.P., Magid, O.A., Lee, M.S., Borisy, A.A., 
Stockwell, B.R. & Keith, C.T. 2007, "Chemical combination effects predict 
connectivity in biological systems.", Molecular systems biology, vol. 3, pp. 80. 
Levine, H.A. & Nilsen-Hamilton, M. 2007, "A mathematical analysis of 
SELEX", Computational biology and chemistry, vol. 31, no. 1, pp. 11-35. 
Levy, S.B. 2008, "Genome size and antibiotic resistance", Antimicrobial Agents and 
Chemotherapy, vol. 52, no. 7, pp. 2696-07. 
Liu, J., Sun, J., Zhang, W., Gao, K. & He, Z. 2008, "HPLC determination of rifampicin 
and related compounds in pharmaceuticals using monolithic column", Journal of 
pharmaceutical and biomedical analysis, vol. 46, no. 2, pp. 405-409. 
Mariappan, T.T., Jindal, K.C. & Singh, S. 2004, "Overestimation of rifampicin during 
colorimetric analysis of anti-tuberculosis products containing isoniazid due to 
formation of isonicotinyl hydrazone", Journal of pharmaceutical and biomedical 
analysis, vol. 36, no. 4, pp. 905-908. 
Mariner, K.R., Ooi, N., Roebuck, D., O'Neill, A.J. & Chopra, I. 2011, "Further 
characterization of Bacillus subtilis antibiotic biosensors and their use for 
antibacterial mode-of-action studies", Antimicrobial Agents and Chemotherapy, vol. 
55, no. 4, pp. 1784-1786. 
McCammon, M.T., Gillette, J.S., Thomas, D.P., Ramaswamy, S.V., Graviss, E.A., 
Kreiswirth, B.N., Vijg, J. & Quitugua, T.N. 2005, "Detection of rpoB mutations 
associated with rifampin resistance in Mycobacterium tuberculosis using denaturing 
gradient gel electrophoresis", Antimicrobial Agents and Chemotherapy, vol. 49, no. 
6, pp. 2200-2209. 
Mikalauskas, A., Parkins, M.D. & Poole, K. 2017, "Rifampicin potentiation of 
aminoglycoside activity against cystic fibrosis isolates of Pseudomonas 
aeruginosa", The Journal of antimicrobial chemotherapy, vol. 72, no. 12, pp. 3349-
3352. 
Mohan, B., Sharda, N. & Singh, S. 2003, "Evaluation of the recently reported USP 




resolve degradation products of rifampicin", Journal of pharmaceutical and 
biomedical analysis, vol. 31, no. 3, pp. 607-612. 
Nayyar, G.M.L., Breman, J.G. & Herrington, J.E. 2015, "The global pandemic of 
falsified medicines: laboratory and field innovations and policy perspectives", The 
American Journal of Tropical Medicine and Hygiene, vol. 92, no. 6 Suppl, pp. 2-7. 
Nayyar, G.M.L., Breman, J.G., Newton, P.N. & Herrington, J. 2012, "Poor-quality 
antimalarial drugs in southeast Asia and sub-Saharan Africa.", The Lancet.Infectious 
diseases, vol. 12, no. 6, pp. 488-496. 
Newton, P.N., Green, M.D. & Fernandez, F.M. 2010, "Impact of poor-quality medicines 
in the 'developing' world", Trends in pharmacological sciences, vol. 31, no. 3, pp. 
99-101. 
Nguyen, V.T., Kwon, Y.S., Kim, J.H. & Gu, M.B. 2014, "Multiple GO-SELEX for 
efficient screening of flexible aptamers", Chemical communications (Cambridge, 
England), vol. 50, no. 72, pp. 10513-10516. 
Norval, P.Y., Blomberg, B., Kitler, M.E., Dye, C. & Spinaci, S. 1999, "Estimate of the 
global market for rifampicin-containing fixed-dose combination tablets", The 
international journal of tuberculosis and lung disease : the official journal of the 
International Union against Tuberculosis and Lung Disease, vol. 3, no. 11, pp. 292-
300. 
Okeke, I.N., Lamikanra, A. & Edelman, R. 1999, "Socioeconomic and behavioral factors 
leading to acquired bacterial resistance to antibiotics in developing 
countries", Emerging infectious diseases, vol. 5, no. 1, pp. 18-27. 
Oz, T., Guvenek, A., Yildiz, S., Karaboga, E., Tamer, Y.T., Mumcuyan, N., Ozan, V.B., 
Senturk, G.H., Cokol, M., Yeh, P. & Toprak, E. 2014, "Strength of selection 
pressure is an important parameter contributing to the complexity of antibiotic 
resistance evolution.", Molecular biology and evolution, vol. 31, no. 9, pp. 2387-
2401. 
Pang, Y., Lu, J., Wang, Y., Song, Y., Wang, S. & Zhao, Y. 2013, "Study of the rifampin 
monoresistance mechanism in Mycobacterium tuberculosis", Antimicrobial Agents 
and Chemotherapy, vol. 57, no. 2, pp. 893-900. 
Pecoul, B., Chirac, P., Trouiller, P. & Pinel, J. 1999, "Access to essential drugs in poor 
countries: a lost battle?", JAMA, vol. 281, no. 4, pp. 361-367. 
Pincock, S. 2003, "WHO tries to tackle problem of counterfeit medicines in 




Piriou, A., Jacqueson, A., Warnet, J.M. & Claude, J.R. 1983, "Enzyme induction with 
high doses of rifampicin in Wistar rats", Toxicology letters, vol. 17, no. 3-4, pp. 301-
306. 
Prankerd, Richard J., Walters, John M., Parnes,Joel H., 1992, "Kinetics for degradation 
of rifampicin, an azomethine-containing drug which exhibits reversible hydrolysis in 
acidic solutions", International Journal of Pharmaceutics, vol. 78, no. 1, pp. 59-67. 
Pressman, A., Moretti, J.E., Campbell, G.W., Muller, U.F. & Chen, I.A. 2017, "Analysis 
of in vitro evolution reveals the underlying distribution of catalytic activity among 
random sequences", Nucleic acids research, vol. 45, no. 14, pp. 8167-8179. 
Projan, S.J. 2007, "(Genome) size matters", Antimicrobial Agents and 
Chemotherapy, vol. 51, no. 4, pp. 1133-1134. 
Qi, Y., Xiu, F.R., Zheng, M. & Li, B. 2016, "A simple and rapid chemiluminescence 
aptasensor for acetamiprid in contaminated samples: Sensitivity, selectivity and 
mechanism", Biosensors & bioelectronics, vol. 83, pp. 243-249. 
Ramachandran, G., Chandrasekaran, V., Hemanth Kumar, A.K., Dewan, P., 
Swaminathan, S. & Thomas, A. 2013, "Estimation of content of anti-TB drugs 
supplied at centres of the Revised National TB Control Programme in Tamil Nadu, 
India", Tropical medicine & international health : TM & IH, vol. 18, no. 9, pp. 
1141-1144. 
Reisbig, Richard R., Woody, A. Young M., Woody,Robert W., 1982, "Rifampicin as a 
spectroscopic probe of the mechanism of RNA polymerase from E. 
coli", Biochemistry Biochemistry, vol. 21, no. 1, pp. 196-200. 
Risha, P.G., Msuya, Z., Clark, M., Johnson, K., Ndomondo-Sigonda, M. & Layloff, T. 
2008, "The use of Minilabs to improve the testing capacity of regulatory authorities 
in resource limited settings: Tanzanian experience", Health policy (Amsterdam, 
Netherlands), vol. 87, no. 2, pp. 217-222. 
Riska, P.F., Su, Y., Bardarov, S., Freundlich, L., Sarkis, G., Hatfull, G., Carriere, C., 
Kumar, V., Chan, J. & Jacobs, W.R.,Jr 1999, "Rapid film-based determination of 
antibiotic susceptibilities of Mycobacterium tuberculosis strains by using a luciferase 
reporter phage and the Bronx Box", Journal of clinical microbiology, vol. 37, no. 4, 
pp. 1144-1149. 
 
Rock, J.M., Lang, U.F., Chase, M.R., Ford, C.B., Gerrick, E.R., Gawande, R., Coscolla, 




Mycobacterium tuberculosis is mediated by an ancestral prokaryotic 
proofreader", Nature genetics, vol. 47, no. 6, pp. 677-681. 
Roger, B. & Boateng, K. 2007, "Bad medicine in the market", World hospitals and health 
services : the official journal of the International Hospital Federation, vol. 43, no. 3, 
pp. 17-21. 
Salem, A.A., Mossa, H.A. & Barsoum, B.N. 2005, "Quantitative determinations of 
levofloxacin and rifampicin in pharmaceutical and urine samples using nuclear 
magnetic resonance spectroscopy", Spectrochimica acta.Part A, Molecular and 
biomolecular spectroscopy, vol. 62, no. 1-3, pp. 466-472. 
Santos, L., Medeiros, M.A., Santos, S., Costa, M.C., Tavares, R. & Curto, M.J.M. 
2001, NMR studies of some rifamycins. 
Sassanfar, M. & Szostak, J.W. 1993, "An RNA motif that binds ATP", Nature, vol. 364, 
no. 6437, pp. 550-553. 
Seo, Y., Nilsen-Hamilton, M. & Levine, H.A. 2014, "A computational study of alternate 
SELEX.", Bulletin of mathematical biology, vol. 76, no. 7, pp. 1455-1521. 
Shakoor, O., Taylor, R.B. & Behrens, R.H. 1997, "Assessment of the incidence of 
substandard drugs in developing countries", Tropical medicine & international 
health : TM & IH, vol. 2, no. 9, pp. 839-845. 
Shewiyo, D.H., Kaale, E., Risha, P.G., Dejaegher, B., Smeyers-Verbeke, J. & Vander 
Heyden, Y. 2012, "Optimization of a reversed-phase-high-performance thin-layer 
chromatography method for the separation of isoniazid, ethambutol, rifampicin and 
pyrazinamide in fixed-dose combination antituberculosis tablets", Journal of 
chromatography.A, vol. 1260, pp. 232-238. 
Shi, F., Li, X., Pan, H. & Ding, L. 2017, "NQO1 and CYP450 reductase decrease the 
systemic exposure of rifampicin-quinone and mediate its redox cycle in 
rats", Journal of pharmaceutical and biomedical analysis, vol. 132, pp. 17-23. 
Shishoo, C.J., Shah, S.A., Rathod, I.S., Savale, S.S. & Vora, M.J. 2001, "Impaired 
bioavailability of rifampicin in presence of isoniazid from fixed dose combination 
(FDC) formulation", International journal of pharmaceutics, vol. 228, no. 1-2, pp. 
53-67. 
 
Singh, S., Mariappan, T.T., Sharda, N.,Singh, B., 2000, "Degradation of Rifampicin, 




Combination Products Under Acid Conditions", Pharmacy and Pharmacology 
Communications Pharmacy and Pharmacology Communications, vol. 6, no. 11, pp. 
491-494. 
Siu, G.K., Zhang, Y., Lau, T.C., Lau, R.W., Ho, P.L., Yew, W.W., Tsui, S.K., Cheng, 
V.C., Yuen, K.Y. & Yam, W.C. 2011, "Mutations outside the rifampicin resistance-
determining region associated with rifampicin resistance in Mycobacterium 
tuberculosis", The Journal of antimicrobial chemotherapy, vol. 66, no. 4, pp. 730-
733. 
Smirnov, I. & Shafer, R.H. 2000, "Effect of loop sequence and size on DNA aptamer 
stability", Biochemistry, vol. 39, no. 6, pp. 1462-1468. 
Spill, F., Weinstein, Z.B., Irani Shemirani, A., Ho, N., Desai, D. & Zaman, M.H. 2016, 
"Controlling uncertainty in aptamer selection", Proceedings of the National 
Academy of Sciences of the United States of America, vol. 113, no. 43, pp. 12076-
12081. 
Stoltenburg, R., Nikolaus, N. & Strehlitz, B. 2012, "Capture-SELEX: Selection of DNA 
Aptamers for Aminoglycoside Antibiotics", Journal of analytical methods in 
chemistry, vol. 2012, pp. 415697. 
Suarez, J., Ranguelova, K., Jarzecki, A.A., Manzerova, J., Krymov, V., Zhao, X., Yu, S., 
Metlitsky, L., Gerfen, G.J. & Magliozzo, R.S. 2009, "An oxyferrous heme/protein-
based radical intermediate is catalytically competent in the catalase reaction of 
Mycobacterium tuberculosis catalase-peroxidase (KatG)", The Journal of biological 
chemistry, vol. 284, no. 11, pp. 7017-7029. 
Tan, Y., Hu, Z., Zhao, Y., Cai, X., Luo, C., Zou, C. & Liu, X. 2012, "The beginning of 
the rpoB gene in addition to the rifampin resistance determination region might be 
needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant 
Mycobacterium tuberculosis isolates from Southern China", Journal of clinical 
microbiology, vol. 50, no. 1, pp. 81-85. 
Taylor, R.B., Shakoor, O., Behrens, R.H., Everard, M., Low, A.S., Wangboonskul, J., 
Reid, R.G. & Kolawole, J.A. 2001, "Pharmacopoeial quality of drugs supplied by 
Nigerian pharmacies", Lancet (London, England), vol. 357, no. 9272, pp. 1933-
1936. 
Tuerk, C., MacDougal, S. & Gold, L. 1992, "RNA pseudoknots that inhibit human 
immunodeficiency virus type 1 reverse transcriptase", Proceedings of the National 




Urban, A., Eckermann, S., Fast, B., Metzger, S., Gehling, M., Ziegelbauer, K., 
Rubsamen-Waigmann, H. & Freiberg, C. 2007, "Novel whole-cell antibiotic 
biosensors for compound discovery", Applied and Environmental Microbiology, vol. 
73, no. 20, pp. 6436-6443. 
van Crevel, R., Nelwan, R.H., Borst, F., Sahiratmadja, E., Cox, J., van der Meij, W., de 
Graaff, M., Alisjahbana, B., de Lange, W.C. & Burger, D. 2004, "Bioavailability of 
rifampicin in Indonesian subjects: a comparison of different local drug 
manufacturers", The international journal of tuberculosis and lung disease : the 
official journal of the International Union against Tuberculosis and Lung 
Disease, vol. 8, no. 4, pp. 500-503. 
van den Boogaard, J., Kibiki, G.S., Kisanga, E.R., Boeree, M.J. & Aarnoutse, R.E. 2009, 
"New drugs against tuberculosis: problems, progress, and evaluation of agents in 
clinical development", Antimicrobial Agents and Chemotherapy, vol. 53, no. 3, pp. 
849-862. 
van der Werf, M.J., Langendam, M.W., Huitric, E. & Manissero, D. 2012, "Multidrug 
resistance after inappropriate tuberculosis treatment: a meta-analysis", The European 
respiratory journal, vol. 39, no. 6, pp. 1511-1519. 
Visser, B.J., Meerveld-Gerrits, J., Kroon, D., Mougoula, J., Vingerling, R., Bache, E., 
Boersma, J., van Vugt, M., Agnandji, S.T., Kaur, H. & Grobusch, M.P. 2015, 
"Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the 
MiniLab(R): a field study", Malaria journal, vol. 14, pp. 273-015-0795-z. 
Wang, J., Rudzinski, J.F., Gong, Q., Soh, H.T. & Atzberger, P.J. 2012, "Influence of 
target concentration and background binding on in vitro selection of affinity 
reagents", PloS one, vol. 7, no. 8, pp. e43940. 
Weaver, A.A., Reiser, H., Barstis, T., Benvenuti, M., Ghosh, D., Hunckler, M., Joy, B., 
Koenig, L., Raddell, K. & Lieberman, M. 2013, "Paper analytical devices for fast 
field screening of beta lactam antibiotics and antituberculosis 
pharmaceuticals", Analytical Chemistry, vol. 85, no. 13, pp. 6453-6460. 
Webb, A.J., Kelwick, R. & Freemont, P.S. 2017, "Opportunities for applying whole-cell 
bioreporters towards parasite detection", Microbial biotechnology, vol. 10, no. 2, pp. 
244-249. 
Weinstein, Z.B. & Zaman, M.H. 2017, "Quantitative bioassay to identify antimicrobial 





Williams, D.L., Spring, L., Collins, L., Miller, L.P., Heifets, L.B., Gangadharam, P.R. & 
Gillis, T.P. 1998, "Contribution of rpoB mutations to development of rifamycin 
cross-resistance in Mycobacterium tuberculosis", Antimicrobial Agents and 
Chemotherapy, vol. 42, no. 7, pp. 1853-1857. 
Williams, K.P., Liu, X.H., Schumacher, T.N., Lin, H.Y., Ausiello, D.A., Kim, P.S. & 
Bartel, D.P. 1997, "Bioactive and nuclease-resistant L-DNA ligand of 
vasopressin", Proceedings of the National Academy of Sciences of the United States 
of America, vol. 94, no. 21, pp. 11285-11290. 
World Health Organization, 2015, Global tuberculosis report 2015. 
World Health Organization, 2014, Companion handbook to the WHO guidelines for the 
programmatic management of drug-resistant tuberculosis. 
World Health Organization, 2012, The evolving threat of antimicrobial resistance: 
options for action. 
World Health Organization, 2011, Survey of the quality of anti-tuberculosis medicines 
circulating in selected newly independent states of the former Soviet Union. 
World Health Organization, 2011, Survey of the quality of selected antimalarial 
medicines circulating in six countries of sub-Saharan Africa. 
World Health Organization, 2007, "Rifampicin, isoniazid and pyrazinamide dispersible 
tablets", WHO drug information. vol. 21, no. 3, pp. 232. 
World Health Organization, 1999, "Counterfeit Drugs: Guidelines for the development of 
measures to combat counterfeit drugs". 
Xu, M., Zhou, Y.N., Goldstein, B.P. & Jin, D.J. 2005, "Cross-resistance of Escherichia 
coli RNA polymerases conferring rifampin resistance to different 
antibiotics", Journal of Bacteriology, vol. 187, no. 8, pp. 2783-2792. 
Yeh, P., Tschumi, A.I. & Kishony, R. 2006, "Functional classification of drugs by 
properties of their pairwise interactions.", Nature genetics, vol. 38, no. 4, pp. 489-
494. 
Zenkin, N., Kulbachinskiy, A., Bass, I. & Nikiforov, V. 2005, "Different rifampin 
sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases 
are not explained by the difference in the beta-subunit rifampin regions I and 




Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R.E. & Yang, H. 2014, 
"A New Bliss Independence Model to Analyze Drug Combination Data.", Journal of 
biomolecular screening, vol. 19, no. 5, pp. 817-821. 
Zhou, Q., Xia, X., Luo, Z., Liang, H. & Shakhnovich, E. 2015, "Searching the Sequence 
Space for Potent Aptamers Using SELEX in Silico", Journal of chemical theory and 
computation, vol. 11, no. 12, pp. 5939-5946. 
Zimmermann, G.R., Lehar, J. & Keith, C.T. 2007, "Multi-target therapeutics: when the 
whole is greater than the sum of the parts", Drug discovery today, vol. 12, no. 1-2, 
pp. 34-42. 
 
	
	
132 
CURRICULUM VITAE 
 
	
	
133 
	
	
134 
	 135 
